Document:

Exhibit 4.2(d)
DESCRIPTION OF THE REGISTRANT'S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
​
The following summary of certain terms of our common stock describes material provisions of, but does not purport to be complete and is subject to, and qualified in its entirety by, our Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”), our Amended and Restated Bylaws (the “Bylaws”), the forms of which are included as exhibits to the Annual Report on Form 10-K of which this Exhibit 4(d) is also included, as well as the relevant portions of the Indiana Corporations Law.
​
DESCRIPTION OF CAPITAL STOCK
        The following is a description of certain material terms of our amended articles of incorporation, bylaws and of certain provisions of Indiana law. The following summary does not purport to be complete and is qualified in its entirety by reference to our amended articles of incorporation and bylaws, and the relevant provisions of Indiana law.
General
Our authorized capital structure consists of:
• 1,100,000,000 shares of common stock, without par value: and
• 15,000,000 shares of preferred stock, without par value
        As of February 14, 2022, there were 325,773,210 shares of common stock and no shares of preferred stock issued and outstanding.
Common Stock
Voting
        The holders of our common stock are entitled to one vote for each share held of record on each matter submitted to a vote of shareholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.
Dividends
        Subject to the rights and preferences of the holders of any series of preferred stock which may at the time be outstanding, holders of our common stock are entitled to such dividends as our board of directors may declare out of funds legally available.
Liquidation Rights
        In the event of any liquidation, dissolution or winding-up of our affairs, after payment of all of our debts and liabilities and subject to the rights and preferences of the holders of any series of our preferred stock, the holders of our common stock will be entitled to receive the distribution of any of our remaining assets.
Other matters
        Holders of our common stock have no conversion, preemptive or other subscription rights and there are no redemption rights or sinking fund provisions with respect to the common stock.
Preferred Stock
        We are authorized to issue up to 15,000,000 shares of preferred stock in one or more series. Our 

amended articles of incorporation authorize our board of directors to determine and state the designations and the relative rights (including, if any, conversion rights, participation rights, voting rights, dividend rights and stated, redemption and liquidation values), preferences, limitations and restrictions of each unissued series. All shares of preferred stock of the same series must be identical with each other in all respects. Our board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock.
        When we issue preferred stock, we will provide specific information about the particular class or series being offered in a prospectus supplement. This information will include some or all of the following:
• the title or designation of the series;
• the number of shares to be included in the series;
• whether dividends, if any, will be cumulative or noncumulative and the dividend rate of the series;
• the conditions upon which and the dates at which dividends, if any, will be payable, and the relation that such dividends, if any, will bear to the dividends payable on any other class or classes of stock;
• the redemption rights and price or prices, if any, for shares of the series and at whose option such redemption may occur, and any limitations, restrictions or conditions on such redemption;
• the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;
• the amounts payable on and the preferences, if any, of shares of the series, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of Ball Corporation;
• whether the preferred stock being offered will be listed on any securities exchange;
•if necessary, a discussion of certain federal income tax considerations applicable to the preferred stock being offered;
• the voting rights, in addition to the voting rights provided by law, if any, of the holders of shares of such series; and
• any other relative rights, preferences, limitations and powers not inconsistent with applicable law or our articles of incorporation or bylaws then in effect.
        Upon issuance, the shares of preferred stock will be fully paid and nonassessable, which means that its holders will have paid their purchase price in full and we may not require them to pay additional funds.
Certain Anti-Takeover Matters
        Certain provisions of our amended articles of incorporation and bylaws, as well as certain provisions of the Indiana Business Corporation Law, may have the effect of encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include:
Classified Board of Directors
        The Indiana Business Corporation Law was amended effective July 1, 2009, to require every corporation that has a class of voting shares registered with the SEC under Section 12 of the Exchange Act to maintain a classified board structure whereby its directors are elected for staggered terms in office. Corporations that were publicly-held at the time the classified board mandate became effective had until July 31, 2009, to amend their bylaws to elect not to be subject to this requirement. We did not amend our bylaws within the prescribed time and, accordingly, we are required to maintain our current classified board structure. Our amended articles of incorporation and bylaws provide for a board of directors, currently consisting of thirteen members which is divided 

into three classes, as nearly equal in number as possible, with directors serving staggered three-year terms. Subject to the right of holders of any series of preferred stock to elect directors, shareholders elect one class constituting approximately one-third of the board of directors for a three-year term at each annual meeting of shareholders. As a result, at least two annual meetings of shareholders may be required for the shareholders to change a majority of the board of directors.
        The classification of directors makes it more difficult to change the composition of the board of directors and instead promotes a continuity of existing management.
Removal of Directors Only for Cause; Filling Vacancies
        Our amended articles of incorporation provide that, subject to the right of holders of any series of preferred stock to elect directors, any director may be removed from office, but only for cause and only by the affirmative vote of the holders of at least 75% of the combined voting power of the outstanding shares of our capital stock entitled to vote generally in the election of directors. Our amended articles of incorporation also provide that, subject to the right of holders of any series of preferred stock to elect directors, any newly created directorships resulting from an increase in the number of directors and any vacancy on the board shall be filled by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the class of directors in which the new directorship was created or the vacancy occurred and until such director's successor shall have been elected and qualified. No decrease in the number of directors constituting the board of directors shall shorten the term of any incumbent director.
        The director removal and vacancy provisions restrict the ability of a third party to remove incumbent directors and simultaneously gain control of the board of directors by filling the vacancies created by removal with its own nominees.
Advance Notice Requirements
        Our bylaws set forth advance notice procedures with regard to shareholder nomination of candidates for election as directors and shareholder proposals of business to be presented at annual meetings of shareholders. These procedures provide that notice of such shareholder nominations or proposals must be given timely in proper written form to the Secretary of Ball Corporation prior to the meeting at which the shareholder nominee or such business is to be considered. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the meeting. To be in proper written form, the notice must contain the information required by our bylaws, including information regarding the proposal and the proponent. The advance notice requirements may have the effect of discouraging a potential acquiror from conducting a proxy contest to elect directors or otherwise attempting to influence or gain control of our company.
Special Meetings of Shareholders
        Our bylaws do not grant shareholders the right to call a special meeting of shareholders. Under our bylaws, special meetings of shareholders may be called only by our chairman of the board or by the board of directors or as otherwise may be required by law.
Restrictions on Certain Related Party Business Combination Transactions
        In order to approve certain business combination transactions involving related parties, our amended articles of incorporation require the affirmative vote of the holders of at least 75% of the then outstanding shares of our capital stock entitled to vote generally in the election of directors. These related party business combination transactions include:
•any merger or consolidation of us or any of our subsidiaries with (1) any related party or (2) any other person or entity who or which is, or after such merger or consolidation would be, an affiliate or associate of the related party;
•any sale, lease, exchange, mortgage, pledge, transfer or other disposition to any related party or an affiliate 

or associate of a related party of any assets of Ball Corporation or any of our subsidiaries having an aggregate fair market value of $10,000,000 or more;
•any issuance or transfer by us or any of our subsidiaries of any securities having an aggregate fair market value of $10,000,000 or more of Ball Corporation or any of our subsidiaries to any related party or an affiliate or associate of a related party in exchange for cash, securities or property (or combination thereof);
• the adoption of any plan or proposal for the liquidation or dissolution of us proposed by or on behalf of a related party or an affiliate or associate of a related party;
•any reclassification of securities or recapitalization of us, or any merger or consolidation of us with any of our subsidiaries or any other transaction that has the effect, either directly or indirectly, of increasing the proportionate share of the outstanding shares of any class of equity or convertible securities of us or any of our subsidiaries that is directly or indirectly owned by any related party or an affiliate or associate of a related party; or
•any agreement, contract or other arrangement providing for any one or more of the transactions mentioned above.
        A related party is a person or entity who or which (1) is the beneficial owner of more than 10% of the voting power of our outstanding capital stock entitled to vote generally in the election of directors; or (2) is one of our affiliates or associates and at any time within the two-year period immediately prior to the date in question was the beneficial owner of 10% or more of the voting power of our outstanding capital stock entitled to vote generally in the election of directors; or (3) is an assignee of or has otherwise succeeded to any shares of our voting stock that were at any time within the two-year period immediately prior to the date in question beneficially owned by any related party, if such assignment or succession shall have occurred in the course of a transaction not involving a public offering within the meaning of the Securities Act.
        The supermajority voting requirement does not apply, however, if:
•the related party business combination transaction is approved by a majority of directors who are unaffiliated with the related party and who were directors before such person or entity became a related party; or
•specified price, form of consideration and procedural requirements have been met.
Amendment of Articles and Bylaws
        Our amended articles of incorporation require the affirmative vote of the holders of at least 75% of the voting power of the outstanding shares of our capital stock entitled to vote generally in the election of directors to alter, amend, repeal or adopt any provision inconsistent with certain provisions of our amended articles of incorporation, including those described above. Our bylaws may be altered, added to, amended or repealed only by our board of directors. Shareholders do not have this authority.
Indiana Business Combinations Statute
        We are subject to Chapter 43, the Business Combinations Chapter, of the Indiana Business Corporation Law. Our bylaws provide that Chapter 42, the Control Share Acquisition Chapter, of the Indiana Business Corporation Law shall not apply to control share acquisitions of shares of our capital stock.
        Subject to exceptions set forth in the Business Combinations Chapter, that Chapter prohibits an Indiana corporation from engaging in certain business combination transactions, including transactions similar to the related party business combination transactions described above, with any interested shareholder for a period of five years following the date that the shareholder first became an interested shareholder, unless the business combination or the purchase of shares made by the interested shareholder on such date is approved by the board of directors of the corporation prior to such date. If prior approval of the board of directors is not obtained, several price and procedural requirements must be met before the business combination may be completed.
        In general, the Business Combinations Chapter defines an interested shareholder as any person who or which (1) is the beneficial owner of 10% or more of the voting power of the outstanding voting shares of the 

corporation or (2) is an affiliate or associate of the corporation and at any time within the five year period immediately before the date in question was the beneficial owner of 10% or more of the voting power of the then outstanding shares of the corporation.
Transfer Agent
        The transfer agent and registrar for our common stock is Computershare Trust Company.Document

Exhibit 10.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
AGREEMENT
THIS AGREEMENT is made effective as of the 16th day of October, 2003, between IDEXX Operations, Inc., a Delaware corporation whose principal place of business is at 6100 East Shelby Drive, Memphis, Tennessee 38141, U.S.A. (“IDEXX”) and Ortho-Clinical Diagnostics, Inc., a New York corporation with offices at 100 Indigo Creek Drive, Rochester, New York, U.S.A. (“OCD”).
WHEREAS, OCD has been a supplier of analyzers for human applications and dry slides, and IDEXX has been a supplier of analyzers for animal applications;
WHEREAS, OCD and IDEXX Laboratories, Inc. (“IDEXX Parent”), the parent company of IDEXX, entered into a supply agreement effective as of January 1, 1999 (the “Prior US Agreement”) with respect to the supply of VITROS slides in the United States and Asia for use on the VETTEST Analyzer (as defined below); and
WHEREAS, OCD and IDEXX Europe B.V. (“IDEXX BV”) entered into a supply agreement effective as of January 1, 1999 with respect to the supply of VITROS slides in Europe for use on the VETTEST Analyzer (the “Prior Europe Agreement”), and intend to amend and restate the Prior Europe Agreement shortly after the date hereof to make certain modifications thereto; and
WHEREAS, OCD, IDEXX Parent and IDEXX BV entered into that certain Operations Agreement effective as of January 1, 1999 (the “Operations Agreement”); and
WHEREAS, OCD, IDEXX Parent and IDEXX BV entered into that certain Amendment, Release and Settlement Agreement dated as of September 12, 2002 (the “Settlement Agreement”) for purposes of, among other things, amending the Prior US Agreement, the Prior Europe Agreement and the Operations Agreement and resolving certain disputes between the parties; and
WHEREAS, OCD and IDEXX desire to expand their relationship in order to create a New Analyzer (as defined below) for animal applications, which will expand the sales of OCD’s dry slides and IDEXX’s analyzers, and to make IDEXX products more competitive;
WHEREAS, OCD and IDEXX through this Agreement desire to combine certain of their respective skills and intellectual property and to invest significant capital to create the New Analyzer and related panel holder design, which is expected to provide a better product offering to customers;
 

 

WHEREAS, this Agreement will ensure IDEXX of a continuing supply of Dry Slides necessary for its continued sale of analyzers, including the New Analyzer.
WHEREAS, OCD and IDEXX now desire to enter into new arrangements for the supply and development of diagnostic slides and analyzers, the terms and conditions of which are documented herein;

NOW THEREFORE, the parties hereby agree as follows:
									
	1.	 	DEFINITIONS

In this Agreement the following expressions shall have the meaning set opposite them.
									
	 	 	 
	“Agreements”	 	This Agreement and the Europe Agreement.
	 	 	 
	“Analyzers”	 	The VETTEST Analyzer and the New Analzyer.
	 	 	 
	“Commencement Date”	 	October 16, 2003.
	 	 	 
	“Dry Slide”	 	A chemical composition, comprising a layered, coated dry film, specifically formulated to analyze for a body constituent, which composition is immediately hydrated by any undiluted bodily fluid, including without limitation a VITROS slide. For avoidance of doubt, the term “Dry Slide” shall not include any assay based on immunomagnetic particle technology or any assay for which the analyte is DNA or RNA.
	 	 	 
	“Effective Rebate Rate”	 	For any year, the weighted average percentage reduction in the purchase price of any slides purchased in such year that IDEXX is entitled to receive pursuant to Section 7.03 hereunder. The calculation of the Effective Rebate Rate is illustrated in Schedule 7.

	 	 	 
	“Europe Agreement”	 	The Prior Europe Agreement, until such time as it is amended and restated as contemplated by the preamble; from and after such time, the “Europe Agreement” shall mean the Prior Europe Agreement as so amended and restated.
	 	 	 
	“Exclusivity Territory”	 	The United States of America and its possessions (including Puerto Rico), Canada, Australia, New Zealand, Japan, India, South Korea and Taiwan.

2

 

									
	 	 	 
	“Existing Special [**] Slides”	 	VETTEST slides that have been [**], as of the date of this Agreement, pursuant to Section 4 of the Operations Agreement.
	 	 	 
	“IDEXX BV”	 	IDEXX Europe B.V., a Netherlands corporation.
	 	 	 
	“New Analyzer”	 	A new chemistry analyzer that uses OCD Dry Slides for veterinary applications, as contemplated by Article 3 of this Agreement, and any updates or modifications to such analyzer.
	 	 	 
	“New Chemistry Slides”	 	As defined in Section 5.06.
	 	 	 
	“New Slide/Panel Design”	 	A new slide format for VETTEST slides to be used in conjunction with the New Analyzer, as well as a panel holder for such slides, as contemplated by Article 3, and any updates or modifications to such design.
	 	 	 
	“New Slides”	 	VETTEST slides that are formatted and packaged in accordance with the New Slide/Panel Design, as contemplated by Article 3.
	 	 	 
	“New Special [**] Slides”	 	VETTEST slides that have been [**] pursuant to Section 7.04 of this Agreement.
	 	 	 
	“PANELS/PROFILES”	 	Packages of VETTEST slides for VETTEST Analyzers consisting of two or more sets of slides of specified chemistries. The initial PANEL and the initial PROFILES shall consist of the slides set forth on Schedule 3 attached hereto, with any changes or additional PANELS/PROFILES to be mutually agreed upon by the parties as specified in Schedule 3.

	 	 	 
	“Prime Rate”	 	For any day in any calendar month, the prime rate of interest as published in the Wall Street Journal on the last business day of the immediately preceding month.

	 	 	 
	“Proportionate Share”	 	The percentage obtained by dividing (i) the number of VETTEST slides purchased by IDEXX in a given period, by (ii) the total number of VETTEST slides

3

 

									
	 	 	 
	 	 	purchased by IDEXX and its affiliates during such period.
	 	 	 
	“Special [**] Slides”	 	Existing Special [**] Slides and New Special [**] Slides.
	 	 	 
	“Term”	 	As defined in Section 18.01.
	 	 	 
	“Territory”	 	Worldwide, except the European Union, Africa, and the countries listed on Schedule 10 attached hereto.

	 	 	 
	“VETTEST Analyzer”	 	The analyzer currently marketed as the VETTEST VT 8008 analyzer and any updates or modifications to such analyzer.
	 	 	 
	“VETTEST slides”	 	Dry Slides currently manufactured by OCD, specially designed, bar coded, labeled, and/or packaged for one or more of the Analyzers in accordance with the terms of this Agreement and supplied by OCD in accordance with the terms and conditions of this Agreement.
	 	 	 
	“VETTEST tips”	 	Metering tips sourced by OCD for use with the VETTEST Analyzer, specially packaged and supplied to IDEXX in accordance with the terms of this Agreement.
	 	 	 
	“VITROS slides”	 	The Dry Slides currently manufactured by OCD for use in any current VITROS analyzer, including without limitation the DT60.

All references to currency in this Agreement shall mean U.S. Dollars unless otherwise specifically indicated.
									
	2.	 	EFFECTIVE DATE OF AGREEMENT
	 		
	 	 	2.01 This Agreement shall become effective upon the Commencement Date. This Agreement shall apply solely within the Territory; except that Sections 3.04, 3.05 and 3.06 shall apply worldwide.
	 		
	3.	 	DEVELOPMENT OF NEW ANALYZER AND NEW SLIDE/PANEL DESIGN

												
	 	3.01	 	IDEXX and its affiliates shall, at their expense, and with cooperation from OCD as set forth below, devote chemistry instrument development resources to the development and launch of the New Analyzer. IDEXX and its affiliates shall use

4

 

												
	 	 	 	commercially reasonable efforts to achieve commercial launch of such analyzer within the United States within [**] years of the Commencement Date. IDEXX shall have control and management of New Analyzer development, and sole approval of New Analyzer specifications.
	 			
	 	3.02	 	IDEXX and its affiliates shall, at their expense, design, develop and validate the New Slide/Panel Design, together with the injection molding tooling for the panel holder and associated label content and art work. IDEXX shall have control and management of New Slide/Panel Design development, and sole approval of New Slide/Panel Design specifications.
	 			
	 	3.03	 	The parties recognize that the design, development and validation of the New Analyzer and the New Slide/Panel Design (the “Development Program”) will benefit from the cooperation of both parties as set forth in this Article 3. Accordingly, OCD agrees, until the third anniversary of the Commencement Date (the “Development Period”), to make technical personnel reasonably available from time to time upon the reasonable request of IDEXX and upon reasonable notice, (i) up to a maximum of 250 hours per calendar quarter, to provide consulting services with respect to development of the New Analyzer, including rendering advice, reviewing proposed instrument designs and making recommendations and (ii) up to a maximum of 250 hours per calendar quarter, to provide consulting services with respect to development of the New Slide/Panel Design, including rendering advice, reviewing proposed slide format and panel holder designs and making recommendations. In connection with such consulting services, OCD may, but shall not be obligated to, disclose materials or other information to IDEXX that OCD considers to be proprietary or confidential. IDEXX agrees that, except as otherwise expressly agreed by OCD in writing, (a) IDEXX shall not acquire any rights to such materials or information, other than as set forth in paragraphs 3.04 through 3.07 below and (b) such materials and information shall be subject to the non-disclosure provisions of Schedule 2 and shall not be used by IDEXX for any purpose for as long as they remain subject to those provisions.

	 			
	 	3.04	 	Ownership of any inventions resulting from the activities of the parties during the Development Period and directly in connection with the Development Program shall vest in the party or parties which, by virtue of the United States patent law, is/are entitled to apply for and obtain patents for said invention. Such inventions the ownership of which (determined as aforesaid) vests (a) solely in IDEXX are hereinafter referred to as “IDEXX Inventions”, (b) solely in OCD are hereinafter referred to as “OCD Inventions” and (c) jointly in IDEXX and OCD are hereinafter referred to as “Joint Inventions”.

	 			
	 	 	 	IDEXX shall be responsible for filing, prosecuting and maintaining patent applications and patents relating to Joint Inventions; provided that IDEXX will reasonably consult with OCD regarding any such applications; and provided

5

 

												
	 	 	 	further that if IDEXX elects not to file, prosecute or maintain any such patent application or patent in any country, OCD will have the right, but not the obligation, at its expense, to file, prosecute and maintain such patent or patent application. All patent applications relating to Joint Inventions shall be drafted and prosecuted by an outside law firm mutually agreed upon by IDEXX and OCD.
	 			
	 	 	 	Except as otherwise set forth in the immediately preceding paragraph, the parties agree to execute and do all things necessary to vest the title and interest in such property rights in the relevant party as set out above, at the expense of said relevant party, which shall pay the costs of the prosecution of all applications for intellectual property rights to which it becomes entitled under this Agreement. A party agreed to be not responsible for the preparation and filing of patent applications on Joint Inventions shall have the right to review such applications a reasonable time prior to filing.
	 			
	 	3.05	 	As used herein, “Background Technology” shall mean all technical information, know-how, processes, techniques, discoveries and inventions (patented, patentable or otherwise) owned by OCD that are not OCD Inventions or Joint Inventions, which OCD in its discretion provides IDEXX to facilitate IDEXX’s development of the New Analyzer or New Slide/Panel Design. To the extent the New Analyzer or New Slide/Panel Design include any Background Technology provided by OCD, OCD hereby grants IDEXX and its affiliates a non-exclusive, worldwide, perpetual, royalty-free, fully paid license, with the right to assign in connection with any assignment of this Agreement, but without the right to sublicense, to make, have made, use, sell, offer to sell and import New Analyzers and the New Slide/Panel Design using Background Technology in the field of Dry Slide diagnostic testing of non-human animals. The licenses granted by this Section 3.05 are subject to any rights of third parties in or to such intellectual property, and are limited to intellectual property that relates to equipment, instrumentation or packaging, rather than slides or reagents. Subject only to the licenses granted by this Section 3.05, OCD shall, retain all right, title and interest in and to the Background Technology, notwithstanding that any such technology is provided to IDEXX or included in the New Analyzer or New Slide/Panel Design. For avoidance of doubt, IDEXX and its affiliates shall have no right to use Background Technology other than in connection with the New Analyzer or the New Slide/Panel Design.

	 			
	 	3.06	 	IDEXX hereby grants OCD and its affiliates a non-exclusive, worldwide, perpetual, royalty-free, fully paid license, with the right to assign in connection with any assignment of this Agreement, but without the right to sublicense, to make, have made, use, sell, offer to sell and import products and services using IDEXX Inventions, in the field of human Dry Slide diagnostic testing. The licenses granted to OCD in this paragraph are subject to any rights of third parties in or to such intellectual property, and are limited to intellectual property that relates to equipment, instrumentation or packaging, rather than slides or reagents.

6

 

												
	 	 	 	For the avoidance of doubt, the licenses granted to OCD in this paragraph shall include the right for OCD to use IDEXX Inventions on any non-human animal species for the development of a product for marketing into the field of human Dry Slide diagnostic testing.
	 			
	 	 	 	OCD hereby grants IDEXX and its affiliates a non-exclusive, worldwide, perpetual, royalty-free, fully paid license, with the right to assign in connection with any assignment of this Agreement, but without the right to sublicense, to make, have made, use, sell, offer to sell and import New Analyzers and the New Slide/Panel Design using OCD Inventions, in the field of Dry Slide diagnostic testing of non-human animals. The licenses granted to IDEXX in this paragraph are subject to any rights of third parties in or to such intellectual property, and are limited to intellectual property that relates to equipment, instrumentation or packaging, rather than slides or reagents.
	 			
	 	3.07	 	OCD hereby agrees that neither it nor its affiliates shall, prior to December 31, 2018, grant any third party the license to make, have made, use, sell, offer to sell and import products and services using Joint Inventions in the field of diagnostic testing of non-human animals; provided, the foregoing restrictions shall not prohibit the assignment by OCD of its interest in such Joint Inventions in connection with any assignment of this Agreement, nor, to the extent that any of the following actions may be deemed to be a license, shall they prohibit OCD from collaborating with any third party in the development of products using Joint Inventions in such field, from having any products using Joint Inventions made by any third party for sale in such field, or from selling any products using Joint Inventions into such field through any third party distributor or sales agent.
	 			
	 	 	 	IDEXX hereby agrees that neither it nor its affiliates shall, prior to December 31, 2018, grant any third party the license to make, have made, use, sell, offer to sell and import products and services using Joint Inventions in field of human diagnostic testing; provided, the foregoing restrictions shall not prohibit the assignment by IDEXX of its interest in such Joint Inventions in connection with any assignment of this Agreement, nor, to the extent that any of the following actions may be deemed to be a license, shall they prohibit IDEXX from collaborating with any third party in the development of products using Joint Inventions in such field, from having any products using Joint Inventions made by any third party for sale in such field, or from selling any products using Joint Inventions into such field through any third party distributor or sales agent.
	 			
	 	 	 	The provisions of this Section 3.07 do not diminish any of the parties’ respective obligations under Article 9 of this Agreement.
	 			
	 	3.08	 	(a) IDEXX shall develop detailed specifications for the New Slide/Panel Design, and the parties shall meet promptly thereafter to review such specifications (the “Design Review”). In connection with the Design Review,

7

 

												
	 	 	 	IDEXX shall also provide OCD with a good faith forecast of the number of New Slides that IDEXX and IDEXX BV anticipate ordering during each of the first five years following the date of the first commercial sale of the New Analyzer (the “Design Forecast”). In addition, IDEXX shall provide OCD with its good faith estimate of its and IDEXX BV’s annual requirements for New Slides during the subsequent three years. Within 60 days after the Design Review, or such other period as the parties may agree, OCD shall provide IDEXX a detailed summary showing OCD’s good faith estimate of (1) the cost to install a production line (including without limitation design costs, engineering costs, equipment costs and validation costs) for the New Slide/Panel Design (“Automation Costs”) and (2) the ongoing expenses per New Slide associated with the formatting and packaging of New Slides that are in excess of OCD’s current expenses for manufacturing and packaging the current VITROS-formatted slides in 50-count cartridges (“Incremental Manufacturing Costs”).

												
	 	 	 	(b) Automation Costs shall exclude the cost of any injection molding tooling associated with the New Slide/Panel Design, for which IDEXX shall be solely responsible. The parties shall mutually agree on the selection of a third party vendor for such tooling. IDEXX shall own such tooling. After installation, OCD shall be solely responsible for the maintenance and repair of any such tooling.
	 			
	 	 	 	(c) Incremental Manufacturing Costs shall be based on the average annual volumes of New Slides set forth in the Design Forecast during the first five years following the date of the first commercial sale of the New Analyzer, and will include the cost of direct labor and materials (including without limitation plastic components and all packaging materials), facility allocation and reasonable overhead, and will exclude depreciation of any Automation Costs.
	 			
	 	 	 	(d) If OCD’s estimated Automation Costs are $[**] or less, and OCD’s estimated Incremental Manufacturing Costs are $[**] or less per New Slide, then OCD shall manufacture and package New Slides in accordance with IDEXX’s specifications for the New Slide/Panel Design and supply them to IDEXX for the Term as provided in this Agreement. In this case, OCD shall be solely responsible for all Automation Costs and all costs of manufacturing such slides, including Incremental Manufacturing Costs, regardless of whether OCD’s actual costs are different than the estimates provided to IDEXX.
	 			
	 	 	 	(e) If OCD’s estimated Automation Costs are greater than $[**], or OCD’s estimated Incremental Manufacturing Costs are greater than $[**] per New Slide, then OCD may elect to be solely responsible for all such costs, in which case OCD shall manufacture and package New Slides in accordance with IDEXX’s specifications for the New Slide/Panel Design and supply them to IDEXX for the Term as provided in this Agreement. In this case, OCD shall be solely responsible for all Automation Costs and all costs of manufacturing such slides,

8

 

												
	 	 	 	including Incremental Manufacturing Costs, regardless of whether OCD’s actual costs are different than the estimates provided to IDEXX.
	 			
	 	 	 	(f) If OCD does not elect to be solely responsible for all costs as provided in paragraph (e) of this Section 3.08, then IDEXX shall have the option of either (1) changing the New Slide/Panel Design to reduce OCD’s costs, such that paragraph (d) of this Section 3.08 applies, or (2) assuming the entire amount (or such lesser portion as the parties mutually agree) of OCD’s estimated Automation Costs that exceeds $[**] and assuming the entire amount (or such lesser portion as the parties mutually agree) of OCD’s estimated Incremental Manufacturing Costs that exceeds $[**] per New Slide, or (3) performing the formatting and packaging of New Slides independently, as more particularly described below.
	 			
	 	 	 	(g) If IDEXX elects to assume a portion of OCD’s Automation Costs or Incremental Manufacturing Costs as set forth in clause (2) of paragraph (f) of this Section 3.08, then (1) in the event actual Automation Costs exceed the amount contemplated by the parties under clause (2) of paragraph (f) of this Section 3.08, IDEXX and OCD shall [**] of such excess Automation Costs and (2) OCD shall be solely responsible for all costs of manufacturing and packaging New Slides, including Incremental Manufacturing Costs, that are not assumed by IDEXX, regardless of whether OCD’s actual costs are different than it had estimated when the parties agreed to the portion to be assumed by IDEXX, and OCD shall supply such slides to IDEXX for the Term as provided in this Agreement.
	 			
	 	 	 	(h) If IDEXX elects to perform the formatting and packaging of the New Slides independently of OCD, then (1) in lieu of New Slides, OCD shall supply IDEXX with VITROS slides in the format currently manufactured for the VITROS mainframe analyzers and/or the VETTEST Analyzer (i.e., VITROS slides packaged in 50-count cartridges, before further formatting and packaging for VETTEST Analyzer requirements), as applicable for New Slides, for the Term as provided in this Agreement, and all references in this Agreement to New Slides or to VETTEST slides, to the extent referring to OCD’s obligation to supply New Slides, shall mean such VITROS slides packaged in 50-count cartridges and (2) solely with respect to New Slides, the prices for Tiers 2 and 3 in the table set forth in Section 7.02 shall be reduced by $[**] per New Slide.
	 			
	 	 	 	(i) The parties acknowledge that the specifications for the New Slide/Panel Design may change after the initial Design Review in accordance with IDEXX’s requirements. If OCD has elected to perform the formatting and packaging of the New Slides, then all incremental costs resulting from such change in specifications, to the extent that they cause Automation Costs to exceed $[**] or Incremental Manufacturing Costs to exceed $[**] per New Slide, shall be borne by the parties as they may agree. If the parties cannot so agree, then IDEXX may make the election provided for in paragraph (h) of this Section 3.08, in which case IDEXX shall reimburse OCD for OCD’s Automation Costs incurred and take

9

 

												
	 	 	 	ownership of any capital equipment and related design materials funded as Automation Costs and developed in connection with OCD’s new production line for the New Slide/Panel Design to the date of IDEXX’s election, and OCD shall cooperate with IDEXX in the transfer of such equipment and materials to IDEXX. If IDEXX has elected to perform the formatting and packaging of the New Slides independently of OCD, and if such change in specifications could reasonably result in a significant reduction in Automation Costs or Incremental Manufacturing Costs, then IDEXX shall notify OCD of such fact and OCD shall have the option to request that the parties conduct a further Design Review in accordance with paragraph (a) of this Section 3.08, and OCD shall be permitted to re-estimate its Automation Costs and Incremental Manufacturing Costs, to require that the parties conduct the cost review, as otherwise provided in this Section 3.08, and to make the election in paragraph 3.08(e).
	 			
	 	 	 	(j) If IDEXX and IDEXX BV shall not have attained [**]% of the Design Forecast during the first five years following the date of the first commercial sale of the New Analyzer, then IDEXX shall reimburse OCD for an amount equal to the product of (a) the Automation Costs borne by OCD, times (b) a fraction, the numerator of which is the number of slides by which IDEXX’s and IDEXX BV’s actual purchases of New Slides falls short of the Design Forecast and the denominator of which is the Design Forecast; provided that, for avoidance of doubt, there shall be no change in the price of New Slides as a result of the failure to attain such percentage of the Design Forecast.
	 			
	 	 	 	(k) If OCD elects to format and package New Slides, and if in the future the through-put capacity of such packaging line is insufficient to meet IDEXX’s and IDEXX BV’s forecasted demand, any additional capital investment or other costs required to meet such demand (other than for injection molding tooling), whether by increasing the through-put capacity of the packaging line or adding a new packaging line, shall be borne by the parties in the same relative proportions as all previous Automation Costs; and IDEXX shall bear the costs for required injection molding tooling.
	 			
	 	 	 	(l) Notwithstanding anything in this Section 3.08 to the contrary, if the Design Forecast indicates that IDEXX and IDEXX BV expect to purchase fewer than [**] New Slides hereunder during the first five years following the date of first commercial sale of the New Analyzer, then OCD may in its sole discretion elect to be released from any obligation to format and package the New Slides, in which event IDEXX’s sole options hereunder shall be either (1) to reduce OCD’s costs to a level that is acceptable to OCD in light of the Design Forecast, or (2) to perform the formatting and packaging of New Slides independently, as more particularly described in paragraph 3.08(h) above.

												
	 	3.09	 	IDEXX acknowledges that it has not relied upon any guarantee or assurance from OCD, express or implied, regarding the technical feasibility of the New Analyzer

10

 

												
	 	 	 	or the New Slide/Panel Design in deciding to engage in the development of the New Analyzer and New Slide/Panel Design, and that OCD shall have no liability with respect to IDEXX’s termination of any of its other product development activities.

									
	4.	 	AGREEMENT TO SUPPLY

												
	 	4.01	 	Subject to the terms and conditions of this Agreement, OCD undertakes to manufacture for IDEXX and to supply to IDEXX VETTEST slides, VETTEST tips and Vetrol controls. OCD shall supply VETTEST slides in compliance with the VETTEST Slide Quality Assurance Procedures set out in Schedule 1. All slides supplied to IDEXX hereunder are supplied solely for sale within the Territory; provided that IDEXX may make limited sales to IDEXX BV solely for purposes of adjusting inventory levels according to unanticipated changes in regional demand. For the avoidance of doubt, nothing in this Agreement shall obligate OCD, with respect to any particular chemistry, to furnish IDEXX with slides for such chemistry in any slit format that OCD does not currently manufacture for such chemistry, or that would otherwise be uneconomical for OCD to supply to IDEXX (other than the slit formats for such chemistry that OCD then sells or has agreed in writing to sell to IDEXX).

	 			
	 	4.02	 	(a) Notwithstanding any other provision of this Agreement, if after [**] the annual volume of VETTEST slides purchased by IDEXX and IDEXX BV is less than [**] slides, then OCD may in its sole discretion elect to be released from any obligation to format and package the New Slides and/or package other VETTEST slides, in which event IDEXX’s sole options hereunder shall be either (x) to accept an increase in slide prices for New Slides and/or other VETTEST slides that is adequate to compensate OCD for any increase in its costs due to such reduction in volume, or (y) with respect to slides for which IDEXX does not accept a price increase under the preceding clause (x), to perform the formatting and packaging of New Slides and/or the packaging of other VETTEST slides, as applicable, independently of OCD.

												
	 	 	 	(b) If IDEXX elects to perform the formatting and packaging of New Slides, then (1) in lieu of New Slides OCD shall supply IDEXX with VITROS slides in the format currently manufactured for the VITROS mainframe analyzers and/or the VETTEST Analyzer (i.e., VITROS slides packaged in 50-count cartridges, before further formatting and packaging for VETTEST Analyzer requirements), as applicable for New Slides, for the Term as provided in this Agreement, and all references in this Agreement to New Slides or to VETTEST slides, to the extent referring to OCD’s obligation to supply New Slides, shall mean such VITROS slides packaged in 50-count cartridges, (2) the prices for Tiers 2 and 3 in the table set forth in Section 7.02 shall be reduced by $[**] per New Slide, (3) IDEXX shall take ownership of any capital equipment and related design materials funded as Automation Costs and developed in connection with OCD’s new production

11

 

												
	 	 	 	line for the New Slide/Panel Design, and OCD shall cooperate with IDEXX in the transfer of such equipment and materials to IDEXX and (4) IDEXX shall reimburse OCD for the book value of such equipment.
	 			
	 	 	 	(c) If IDEXX elects to perform the packaging of VETTEST slides other than New Slides, then (1) in lieu of such other VETTEST slides OCD shall supply IDEXX with VITROS slides in the format currently manufactured for the VETTEST Analyzer (i.e., VITROS slides packaged in 50-count cartridges, before further formatting and packaging for VETTEST Analyzer requirements) for the Term as provided in this Agreement, and all references in this Agreement to VETTEST slides, to the extent referring to OCD’s obligation to supply such slides (other than New Slides), shall mean such VITROS slides packaged in 50-count cartridges, (2) the prices for Tiers 1, 2 and 3 in the table set forth in Section 7.02 shall be reduced by $[**] per slide for VETTEST slides (other than New Slides), (3) IDEXX shall take ownership of OCD’s packaging lines for VETTEST slides (other than New Slides), except equipment which OCD requires for the packaging of slides for the VITROS DT60 (or next generation OCD analyzer), but in any event including the VETTEST “panel assembly machine” (PAM) line which is used currently to package PANELS/PROFILES, and OCD shall cooperate with IDEXX in the transfer of such packaging line(s) to IDEXX and (4) IDEXX shall reimburse OCD for the book value of such transferred equipment.
	 			
	 	 	 	(d) In either case if IDEXX elects to perform the formatting and packaging of New Slides and/or the packaging of other VETTEST slides independently, the parties shall cooperate to determine an appropriate timetable for the transfer of responsibilities to IDEXX, such that the supply of slides to IDEXX shall continue without interruption.
	 			
	 	 	 	(e) For the avoidance of doubt, nothing in this Agreement shall obligate OCD to transfer to IDEXX any capital equipment used by OCD in the manufacture of VITROS slides.

									
	5.	 	FORECASTS, COMMITMENTS AND ORDERS

												
	 	5.01	 	Attached hereto as Schedule 4 are aggregate Purchase Commitments by IDEXX and IDEXX BV for VETTEST slides for the VETTEST Analyzer for calendar years 2003 through and including 2010. The Purchase Commitments constitute the aggregate anticipated minimum aggregate purchase quantities by IDEXX and IDEXX BV for single chemistry VETTEST slides and PANELS/PROFILES slides in the indicated calendar years.

	 			
	 	 	 	Existing Special [**] Slides, New Special [**] Slides and New Chemistry Slides shall be excluded from the determination of IDEXX’s and IDEXX BV’s slide purchases for purposes of achieving their aggregate Purchase Commitments under Section 5.01 of this Agreement or the Europe Agreement, as the case may be.

12

 

												
	 	 	 	Failure by IDEXX and IDEXX BV to purchase, in the aggregate, at least the indicated Purchase Commitment quantities of each type of slides in any year may subject IDEXX to the requirement to make a payment to OCD as set forth in Section 5.02 below, but such failure shall in no event otherwise be deemed to be a breach of this Agreement.
	 			
	 	5.02	 	If IDEXX and IDEXX BV fail to purchase in the aggregate the quantities of slides for the VETTEST Analyzer set forth as Purchase Commitments on Schedule 4 in a particular calendar year, unless there has been a Material Adverse Change (as defined in the following paragraph), IDEXX shall pay, or shall cause IDEXX BV to pay, to OCD within 30 days after the end of such calendar year [**]% of the product of (i) the number of each type of slides (single or PANELS/PROFILES) by which IDEXX and IDEXX BV have in the aggregate fallen short of the Purchase Commitment and (ii) the lowest per-slide price for the applicable type of slides under either of the Agreements.

	 			
	 	 	 	For the purposes of this Section 5.02, “Material Adverse Changes” shall mean material changes in the veterinary clinical chemistry markets which result from (a) the commercial introduction into the veterinary market, other than by IDEXX or its affiliates, of a technology not previously available in the veterinary clinical chemistry market, (b) the eradication of one or more diseases, or the development of new disease therapies, treatments or diagnostics, which significantly reduces demand for veterinary clinical chemistry testing or (c) the inability or unwillingness of OCD to supply VETTEST or VITROS slides in accordance with IDEXX’s Annual Purchase Forecasts pursuant to Section 5.04 below. Whether a Material Adverse Change has occurred will be determined by reference to the effect of a change in the veterinary clinical chemistry market on IDEXX and IDEXX BV taken as a whole, and not on either individually.

	 			
	 	 	 	The parties shall discuss in good faith any assertion by IDEXX or IDEXX BV that a Material Adverse Change has occurred or is continuing. If the parties agree that a Material Adverse Change has occurred or is continuing, they shall negotiate in good faith with respect to appropriate reductions in Purchase Commitments, VETTEST slide prices (including single and PANELS/PROFILES slides) and/or amounts which would otherwise be payable pursuant to the first sentence of this Section 5.02 to appropriately allocate the effects of such Material Adverse Change on the parties.
	 			
	 	5.03	 	Order and delivery of VETTEST slides (including PANELS/PROFILES) shall be made in multiples of 100 boxes. Unless otherwise agreed between the parties in any particular case, IDEXX shall place orders for slides four times per calendar year, for delivery in each calendar quarter of the year. Each order shall specify a business day delivery date for each delivery, which shall be not less than three months after the order date. Unless otherwise agreed between the parties in any

13

 

												
	 	 	 	particular case the number of deliveries shall be limited to four per year. IDEXX shall order quantities for delivery in any quarter in accordance with its good faith estimates of actual demand, with allowance for reasonable inventory management requirements and consistent with IDEXX’s stated desire to minimize its inventory levels.
	 			
	 	 	 	Order and delivery of the VETTEST tips shall be made in multiples of 10,000 tips (20 cartons each containing 500 tips). Unless otherwise agreed between the parties in any particular case, the number of orders and deliveries of the VETTEST tips and Vetrols shall be limited to two in each year. OCD shall deliver the VETTEST tips and Vetrols in the ordered quantities in each year.
	 			
	 	5.04	 	Not later than October 1 of each year, commencing October 1, 2003, IDEXX shall notify OCD of the aggregate forecasted requirements of IDEXX for the subsequent calendar year for each of the VETTEST slides (single slides and PANELS/PROFILES slides for the VETTEST Analyzer and New Slides) (each such notification, an “Annual Purchase Forecast”). The aggregate order quantities in the subsequent year for each of the VETTEST slides shall be within ±25% of such aggregate Annual Purchase Forecast unless the parties otherwise agree. As long as slide orders do not exceed the applicable Annual Purchase Forecast by more than 25%, OCD shall deliver the slides in accordance with the orders. The Annual Purchase Forecasts constitute non-binding forecasts for OCD’s planning purposes and shall also be the basis for determining estimated slide pricing pursuant to Section 7.02 below and the cash rebate pursuant to Section 7.03 below.

	 			
	 	 	 	In addition to the Annual Purchase Forecast, IDEXX shall furnish to OCD updated quarterly forecasts of the aggregate requirements of IDEXX for VETTEST slides in the four succeeding calendar quarters. The parties understand that such forecasts are merely estimates to assist OCD in production planning and are not to be considered orders or binding in any way.
	 			
	 	 	 	The parties shall further coordinate with one another to keep OCD apprised of IDEXX’s current and anticipated inventories of stock keeping units and relevant conditions in the veterinary market. The provisions of this paragraph shall terminate immediately upon delivery by OCD of a notice of termination of Section 9.04.
	 			
	 	5.05	 	In the event that IDEXX in any year notifies OCD that it wishes to order quantities which exceed the quantities mentioned in Section 5.04 above by more than 25%, OCD will endeavor to supply the excess quantities and notify IDEXX of the extent of its ability to so supply.
	 			
	 	5.06	 	It is understood and agreed that orders for the VETTEST slides shall include only those chemistries set forth in Schedule 5 hereto, as amended from time to time by

14

 

												
	 	 	 	agreement of the parties. IDEXX may at any time request that the additional chemistries listed on Schedule 8 hereof, in the form they are available at the Commencement Date to the human market on VITROS slides, be added as VETTEST slides to Schedule 5 (any VETTEST slides so added, containing such additional chemistries, are referred to herein as “New Chemistry Slides”). Prior to adding a New Chemistry Slide on Schedule 5, the parties will negotiate in good faith to determine the initial price for such slides in accordance with the immediately following paragraph and shall set forth such price on Schedule 6. IDEXX shall have the right, from time to time, to elect to remove any New Chemistry Slides from Schedule 5, and Schedule 5 and Schedule 6 shall be updated to reflect such removal. IDEXX acknowledges that neither this nor any other provision of this Agreement shall obligate OCD to supply IDEXX with any slide or other product based on any technology that is not incorporated in the VITROS slides or VETTEST slides that OCD sells as of the date hereof.

	 			
	 	 	 	Until [**], the price per slide for any New Chemistry Slides shall be the greater of $[**] and [**] (as determined by OCD in good faith and taking into account IDEXX’s and IDEXX BV’s good faith forecast for the quantity of the chemistry in question). For orders placed for delivery during each calendar year beginning with [**], if [**] of any New Chemistry Slide is determined to be greater than $[**] (as determined by OCD in good faith and taking into account IDEXX’s and IDEXX BV’s good faith forecast for the quantity of the chemistry in question), then the minimum price per slide for such New Chemistry Slides shall be [**]; provided, that so long as IDEXX and IDEXX BV order [**] or more of such slides in the aggregate in any calendar year, the minimum price per slide for such New Chemistry Slides shall not exceed $[**]. OCD shall have the right, from time to time and in good faith, to revise its determination of [**] of any New Chemistry Slide that is priced on Schedule 6 if IDEXX’s and IDEXX BV’s aggregate actual annual orders of such slide fall below [**], and Schedule 6 shall be updated to reflect such revised [**].

	 			
	 	 	 	In the event that a chemistry listed in Schedule 5 should become known by OCD to be unavailable at any future date during the Term, OCD will so notify IDEXX at the earliest practicable date, and the parties shall cooperate to determine an appropriate course of action.

									
	6.	 	DELIVERY

												
	 	6.01	 	Following acknowledgement by OCD of each order placed by IDEXX and on or before the delivery due date, OCD shall complete delivery of the appropriate quantity of slides and tips within ± 10%. Deviations of delivery quantities from order quantities within the ± 10% range may be compensated by IDEXX in the first subsequent order placed, subject to Section 5. In the event of a price increase for one or more of the VETTEST slides, such compensating quantity of such slides shall be processed at the previous lower price.

15

 

												
	 	6.02	 	Order and delivery for all purchases hereunder shall be F.O.B. OCD’s facility in the U.S.A.
	 			
	 	6.03	 	Unless otherwise advised in writing by OCD to IDEXX, OCD shall pack the VETTEST slides in accordance with OCD’s standard shipping configuration which is known to IDEXX and which at the Commencement Date contains approximately 60 cases per pallet, each case containing 100 boxes of slides.
	 			
	 	6.04	 	The parties shall reasonably cooperate to identify and implement potential savings for both parties, consistent with the principles of lean manufacturing across the value chain, in all processes in their relationship, including without limitation improvements relating to slide manufacturing, packaging, ordering, build schedules, component purchasing, delivery schedules, quality testing and calibration processes, and product distribution processes (including direct shipment to IDEXX distributors and end-users), and including without limitation, identifying and implementing processes to reduce the number of slide lots supplied to IDEXX and to reduce IDEXX calibration time; provided, that neither party shall be obligated to implement a process change for which its net costs exceed its net benefits.

									
	7.	 	PRICES

												
	 	7.01	 	Subject to the provisions of Sections 3.08 and 4.02 that contemplate OCD’s delivery of slides in 50-count cartridges if IDEXX elects to format and/or package slides independently, all references to pricing for VETTEST slides in this agreement refer to the completed and packaged product in form ready for delivery to an end-user. The initial prices for each of the VETTEST slides (including the PANELS/ PROFILES) shall be as set forth in Schedule 5 hereto. Such prices are broken out to provide prices for each individual product code for the following geographic regions (additional regions may be added, and changes within regions may be agreed to, from time to time in writing by the parties):

						
	 	US—United States, Canada and all other countries not identified in this Section 7.01;

						
	 	Asian—Brunei, China, Hong Kong, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand, Viet Nam.

						
	 	Australia/New Zealand

												
	 	 	 	IDEXX agrees that OCD may audit IDEXX’s books and records to verify sales of VETTEST slides in any region.

16

 

												
	 	7.02	 	(a) The prices set forth in Schedule 5 shall remain in effect for orders placed through December 31, [**].

												
	 	 	 	(b) For orders placed for delivery during each calendar year beginning with [**], the price for each VETTEST slide listed on Schedule 5 (whether New Slides, single chemistry VETTEST slides for the VETTEST Analyzer, or per slide in PANELS/PROFILES, and, for avoidance of doubt, including New Chemistry Slides, subject to Section 5.06), within the respective volume tiers set forth below (aggregating for this purpose purchases by IDEXX and IDEXX BV) shall be as set forth for such volume tier; provided, that Existing Special [**] Slides and New Special [**] Slides shall not be priced by reference to the volume tiers but will be priced as otherwise set forth below. For purposes of determining purchase volumes, up to [**] Existing Special [**] Slides shall be included in the determination, and all other Existing Special [**] Slides and New Special [**] Slides shall be excluded from the determination. The stated price shall apply only to slides purchased within the corresponding volume tier, and only with respect to the quantities within such tier.

															
	 	 	 	 	 
	Annual Volume Tier	 	Price per Slide
	
	 	

	Tier 1: Up to [**]
	 	$	[**]	 
	Tier 2: In excess of [**], but not exceeding [**]
	 	$	[**]	 
	Tier 3: In excess of [**]
	 	$	[**]	 

												
	 	 	 	For all orders for Existing Special [**] Slides, the price per slide shall be as agreed between the parties pursuant to Section 4 of the Operations Agreement.
	 			
	 	 	 	For all orders for New Special [**] Slides, the price per slide shall be as agreed between the parties pursuant to Section 7.04 of this Agreement.
	 			
	 	 	 	Notwithstanding the foregoing, the price per slide for any New Chemistry Slide that is priced on Schedule 6 shall never be lower than the greater of (a) the minimum price as determined in accordance with Section 5.06 and identified on Schedule 6 as amended from time to time and (b) the price that would otherwise apply pursuant to the pricing tiers set forth above.

	 			
	 	 	 	Promptly after IDEXX and IDEXX BV provide their aggregate Annual Purchase Forecast for a calendar year pursuant to Section 5.04 and Section 5.04 of the Europe Agreement, the parties shall calculate the weighted average price of slides included in such forecast (the “First Estimated Blended Price”).

17

 

												
	 	 	 	Upon determination of the First Estimated Blended Price applicable to a calendar year, for each order placed by IDEXX for delivery during the first three calendar quarters of such year, the amount invoiced and paid per slide listed on Schedule 5 shall be the First Estimated Blended Price.

	 			
	 	 	 	Before IDEXX places its order for the fourth calendar quarter of the year, the parties shall review IDEXX’s and IDEXX BV’s respective fourth-quarter orders and re-calculate the weighted average price of slides based on IDEXX’s and IDEXX BV’s aggregate actual orders for the first three quarters and their orders for the fourth quarter (the “Second Estimated Blended Price”). If the Second Estimated Blended Price is different than the First Estimated Blended Price, the amount invoiced and paid per slide listed on Schedule 5 shall be the Second Estimated Blended Price. In addition, either party may calculate the resulting adjustment (up or down) for each slide delivered for the first three quarters to reflect the difference between the First Estimated Blended Price and the Second Estimated Blended Price, such that the amount paid by IDEXX for all slides delivered during the first three calendar quarters shall equal the Second Estimated Blended Price. If the adjustment is an upwards adjustment, then IDEXX shall pay OCD the aggregate amount of such adjustment, together with interest on such amount (calculated as set forth below), within 30 days of OCD’s request for such payment. If the adjustment is a downwards adjustment, then OCD shall pay IDEXX the aggregate amount of such adjustment, together with interest on such amount (calculated as set forth below), within 30 days of IDEXX’s request for such payment (or, at IDEXX’s option, apply such amount as a credit against IDEXX’s third or fourth quarter invoice).

	 			
	 	 	 	Within 30 days after the end of the year (or 30 days after IDEXX and IDEXX BV complete payment in full for all slides purchased during the year, if later), the parties shall perform a final calculation of the weighted average price based on all slides ordered by IDEXX and IDEXX BV and delivered during the year (the “Final Blended Price”). If the Final Blended Price is different than the Second Estimated Blended Price, then IDEXX or OCD, as the case may be, shall make a final payment to the other, so that the final amount paid by IDEXX per slide for all slides ordered and delivered during the year shall equal the Final Blended Price. The party obligated to make such final payment shall do so within 30 days after the determination of the Final Blended Price.

	 			
	 	 	 	Any adjustment payments made pursuant to either of the immediately preceding paragraphs, and any overdue payments by OCD or IDEXX of any amounts owed to the other pursuant to this Section 7.02, shall bear interest at a rate per annum equal to the Prime Rate. Such interest shall be calculated based on a 365-day year and the actual number of days elapsed since the due date for the applicable payment to which it relates.

18

 

												
	 	 	 	For avoidance of doubt, the blended price calculations of this Section 7.02 shall apply only to chemistries listed on Schedule 5, and only after calendar year [**].

												
	 	 	 	(c) OCD may, at its option, increase all prices for slides ordered for delivery (i) on or after January 1, [**] by an amount not to exceed [**]% of the “PPI Increase” (as defined below), provided that OCD may not increase prices under this clause (i) unless the PPI Increase is greater than [**]%; and (ii) on or after January 1, [**]by an amount (x) as provided in the preceding clause (i) or (y) by an amount not to exceed [**]% of the PPI Increase, provided that OCD may not increase prices under this subclause (y) unless the PPI Increase is greater than [**]%. OCD may calculate the PPI Increase each year beginning in [**], and any resulting price increase shall be effective for orders placed for delivery during the following calendar year and thereafter, unless and until increased again in accordance with the procedures set forth in this paragraph. For purposes of this Agreement, the “PPI Increase” shall be calculated by dividing (x) the average monthly “PPI” level for the most recent 12-month period ending with and including June of the year in which the PPI Increase is being calculated (each such period, a “Measurement Period”), by (y) the average monthly PPI level for the 12-month period immediately preceding that described in clause (x) (the “Baseline Period” with respect to such Measurement Period), then subtracting 1 and converting the remaining fraction into a percentage. All calculations shall be based on the latest version of the PPI level published as of the date the calculation is made. For purposes of this Agreement, “PPI” means the United States Producer Price Index – [**] (not seasonally adjusted), current series identification [**], as published by the Bureau of Labor Statistics on its Web site (www.bls.gov/ppi), or if not available from such Web site, then as published by the Bureau of Labor Statistics in its monthly periodical “Producer Price Indexes.” OCD shall give IDEXX written notice of any price increase pursuant to this paragraph 7.02(c) at least 120 days before the beginning of the calendar year for which a price increase is to take effect; otherwise, the prices shall remain unaffected by such increase for such year.

	 			
	 	 	 	(d) With respect to slides ordered for delivery on or after January 1, [**], if OCD’s aggregate cost of [**] (as defined below) for the most recent Measurement Period has increased on a per VETTEST slide basis as compared with the applicable Baseline Period by an amount that exceeds the PPI Increase for such Measurement Period as applied to the [**] for such Baseline Period, on a per VETTEST slide basis, then OCD shall be permitted to increase the price of each slide sold to IDEXX by the amount of such excess. “[**]” means [**] that are [**]. Schedule 9 attached hereto contains an example, for illustration purposes only, of the calculations described in this paragraph 7.02(d) and in paragraph 7.02(e).

	 			
	 	 	 	(e) With respect to slides ordered for delivery on or after January 1, [**], if IDEXX’s share of Special Event Costs (as defined below) for the most recent

19

 

												
	 	 	 	Measurement Period has increased on a per VETTEST slide basis as compared with the applicable Baseline Period by an amount that exceeds [**] above the PPI Increase for such Measurement Period as applied to IDEXX’s share of Special Event Costs for such Baseline Period, on a per VETTEST slide basis, then OCD shall be permitted to increase the price of each slide sold to IDEXX by the amount of such excess. “Special Event Costs” means the aggregate net amount of (i) [**] with respect to [**] on which [**], (ii) [**] in the [**], and (iii) [**] as a result of [**]. “IDEXX’s share” of any of the foregoing shall mean the [**] that is attributable to the [**].

	 			
	 	 	 	(f) OCD shall give IDEXX written notice of any price increase pursuant to paragraph 7.02(d) or 7.02(e) at least 120 days before the beginning of the calendar year for which a price increase is to take effect; otherwise, the prices shall remain unaffected by such increase for such year. Any price increase pursuant to paragraph 7.02(d) or 7.02(e) shall be effective for orders placed for delivery during the following calendar year and thereafter, unless and until (i) increased again in accordance with the procedures set forth in such paragraphs or (ii) there occurs a decrease in any of the costs upon which the price increase was based (or any such cost that was relevant in one measuring period is not relevant in subsequent periods, for example, certain validation or other one-time costs incurred for compliance purposes), in which event IDEXX’s price per slide shall be reduced to the extent of such decrease (or one-time cost). In addition, OCD agrees to consider in good faith any request by IDEXX to reimburse OCD pursuant to paragraph 7.02(e) by a process other than an increase in slide prices, such as a lump sum payment or series of payments. Furthermore, with respect to any one-time cost or other temporary cost lasting no more than one year, IDEXX shall have the right to make such reimbursement in equal periodic payments (no less frequently than quarterly) over a period that is no longer than one year.
	 			
	 	 	 	(g) OCD shall give IDEXX reasonable detail as to its incremental [**] costs and incremental Special Event Costs on which it seeks to base a price increase pursuant to paragraph 7.02(d) or 7.02(e) or otherwise pass on to IDEXX pursuant to paragraph 7.02(f); provided, however, that IDEXX shall not have any right to obtain any details concerning OCD’s actual costs (other than such incremental cost differences used in such calculation).
	 			
	 	 	 	(h) At any time after OCD’s aggregate annual sales volume of VITROS slides and VETTEST slides shall have declined more than [**]% from [**], the parties shall, at OCD’s request, discuss appropriate pricing of slides under this Agreement. Neither party shall be obligated to agree to any price change under this Section 7.02(h).
	 			
	 	 	 	(i) OCD agrees that IDEXX shall have the right, no more than once per calendar year, to cause a nationally recognized independent accounting firm to conduct an audit, on reasonable advance notice and during normal business hours,

20

 

												
	 	 	 	of OCD’s books and records to the extent reasonably necessary to confirm OCD’s price increase calculations under this Section 7.02. Any report prepared by such independent accounting firm shall contain such firm’s conclusion concerning the validity of OCD’s price increase; provided, however, that such report shall not contain, and IDEXX shall not have any right to obtain, any details concerning OCD’s actual costs (other than incremental cost differences used in the calculation of OCD price increases).
	 			
	 	 	 	(j) IDEXX agrees that OCD may audit IDEXX’s books and records relating to orders of VETTEST slides to confirm the pricing calculations under this Section 7.02.

												
	 	7.03	 	The provisions of this Section 7.03 shall apply only to purchases of VETTEST slides for the VETTEST Analyzer during calendar years [**]. IDEXX shall be entitled to receive its Proportionate Share (based on sales during a calendar year) of a cash rebate in the amount set forth below if the total aggregate slide purchases by IDEXX and IDEXX BV, in calendar year [**], exceed the aggregate quantities set forth below:

																					
	 	 	 	 	 	 	 
	 	 	 	 	Incremental Cash Rebate –
	Annual Slide Purchases	 	% Off Purchase Price
	 	0	[**]
	 	 	[**]	%
	 	 	[**]
	 	 	[**]	%
	 	 	[**]
	 	 	[**]	%
	 	 	[**]
	 	 	[**]	%
	 	 	[**]
	 	 	[**]	%
	 	 	[**]
	 	 	[**]	%
	        [**] and above
	 	 	[**]	%

												
	 	 	 	The rebate amounts set forth above constitute a percentage reduction in the purchase price of any slides (including both single slides and PANELS/PROFILES slides) purchased above the corresponding quantity. The percentage amounts are incremental (as opposed to cumulative) and relate only to the quantities set forth opposite it. For example, if IDEXX and IDEXX BV were to purchase, in the aggregate, [**] slides in calendar year [**], they would not be entitled to a [**]% price reduction on all slides that they purchased in such year, rather, they would be entitled to receive (i) [**] purchase price reduction on the first [**] slides purchased, (ii) a [**]% purchase price reduction on all slides purchased over [**], up to and including [**], (iii) an [**]% purchase price reduction on all slides purchased over [**] up to and including [**], and (iv) a [**]% purchase price reduction on all slides purchased over [**] up to and including the [**] slides that they purchased. The foregoing notwithstanding, it is understood and agreed that if IDEXX and IDEXX BV do not, in the aggregate, achieve the aggregate Purchase Commitments set forth in Section 5 in any calendar year, then they shall not be entitled to receive a rebate for such year.

21

 

												
	 	 	 	In the beginning of calendar year [**], OCD shall calculate an estimated Effective Rebate Rate (the “Estimated Rebate Rate”) based on the lesser of (i) IDEXX’s and IDEXX BV’s aggregate Annual Purchase Forecast for such year and (ii) [**]% of the total aggregate number of slides that IDEXX and IDEXX BV together purchased in [**]. The Estimated Rebate Rate for calendar year [**] shall be such that the average VETTEST slide price for [**], after giving effect to the rebate, shall be $[**]. Not later than thirty (30) days after the end of each of the first three calendar quarters of [**] (or thirty days after IDEXX and IDEXX BV complete payment in full for slides purchased during such quarter, if later), OCD shall pay to IDEXX its Proportionate Share (based on purchases during the preceding quarter) of an amount equal to the aggregate estimated rebate payment that IDEXX and IDEXX BV would together be entitled to receive in such quarter (the “Estimated Rebate Payment”). The Estimated Rebate Payment for any such quarter shall be calculated by (i) multiplying the Estimated Rebate Rate in effect during such quarter by the total aggregate purchase price for the VETTEST slides purchased by IDEXX and IDEXX BV during such quarter and (ii) subtracting from such amount an amount equal to [**]% of the total calculated in clause (i) above. The foregoing notwithstanding, if, in calendar year [**], (i) IDEXX’s and IDEXX BV’s total aggregate slide orders for the immediately preceding calendar year were less than [**]% of their aggregate Annual Purchase Forecast for such preceding calendar year or (ii) OCD determines, in its reasonable discretion, at any time after the end of the second calendar quarter of such calendar year, or IDEXX indicates at any time, that IDEXX and IDEXX BV are reasonably unlikely to meet their aggregate Annual Purchase Forecast for such year, then OCD shall have the right to recalculate the Estimated Rebate Rate based on IDEXX’s and IDEXX BV’s aggregate Purchase Commitment for such year (such recalculated rate being hereinafter referred to as the “New Estimated Rebate Rate”). If OCD elects to recalculate the Estimated Rebate Rate pursuant to the immediately preceding sentence, (i) OCD shall notify IDEXX in writing which notice shall set forth the New Estimated Rebate Rate, (ii) OCD shall calculate all remaining quarterly Estimated Rebate Payments (which may include the Estimated Rebate Payment for the second calendar quarter) using the New Estimated Rebate Rate and (iii) all such Estimated Rebate Payments shall be made in accordance with this sub-clause 7.03, except that such Estimated Rebate Payments shall be less the amount by which the aggregate Estimated Rebate Payments received by IDEXX and IDEXX BV during the then current calendar year exceed the aggregate Estimated Rebate Payments they would have received during such calendar year if the New Estimated Rebate Rate were in effect from the first day of such calendar year.

	 			
	 	 	 	Notwithstanding any provision in this Agreement to the contrary, OCD shall not be required to pay to IDEXX its Proportionate Share of any Estimated Rebate Payments in any calendar year if (A) any amounts payable to OCD from IDEXX pursuant to this Agreement are overdue, unless such amounts are being disputed

22

 

												
	 	 	 	in good faith by IDEXX, or (B) OCD determines in its reasonable judgment that IDEXX and IDEXX BV are reasonably unlikely to meet their aggregate Purchase Commitments for such year. In the case of clause (B) above, OCD shall have the right to make such determination at any time after the end of the second calendar quarter of calendar year [**], as the case may be (or such earlier time as IDEXX or IDEXX BV indicates (through an Annual Purchase Forecast or otherwise) that their aggregate slide purchases are reasonably likely to be less than their aggregate Purchase Commitment for such year), provided that OCD has consulted with IDEXX and given IDEXX an opportunity (which opportunity shall be available for a period of not less than 5 business days nor more than 10 business days) to demonstrate its and IDEXX BV’s intent and ability to meet their aggregate Purchase Commitments for such year. For the avoidance of doubt, OCD’s obligation to make any Estimated Rebate Payments shall be suspended during the period referred to in the immediately preceding sentence and the days in such period shall not be counted when determining the date by which the next scheduled Estimated Rebate Payment is due and payable. If, after fulfilling the requirements set forth in this paragraph, OCD makes the determination described in clause (B) above, OCD (i) shall promptly notify IDEXX in writing of its determination and (ii) shall thereafter have the right to cease making Estimated Rebate Payments for the remainder of such calendar year.
	 			
	 	 	 	Not later than thirty (30) business days after the end of the last calendar quarter of calendar year [**], as the case may be (or thirty days after IDEXX and IDEXX BV complete payment in full for slides purchased during such quarter, if later), OCD shall pay to IDEXX its Proportionate Share (based on purchases during such calendar year) of the amount by which (i) the Effective Rebate Rate multiplied by the total aggregate purchase price for VETTEST slides purchased by IDEXX and IDEXX BV during such calendar year exceeds (ii) the total aggregate amount of the Estimated Rebate Payments made by OCD to IDEXX and IDEXX BV during such calendar year. If the amount in clause (ii) above exceeds the amount in clause (i) above, OCD shall deliver to IDEXX a written notice of such fact (a “Reimbursement Notice”) and IDEXX shall pay to OCD, within thirty (30) days of receipt of such notice an amount in cash equal to its Proportionate Share of the amount of such excess.

	 			
	 	 	 	Notwithstanding the foregoing, if IDEXX and IDEXX BV do not achieve their aggregate Purchase Commitment in calendar year [**], as the case may be, then IDEXX shall return all Estimated Rebate Payments received from OCD for such year no later than thirty (30) days after the end of such calendar year.
	 			
	 	 	 	An illustrative representation of the foregoing rebate calculation methodology is attached hereto as Schedule 7.

	 			
	 	 	 	Notwithstanding any other provision of this Section 7.03, if any amounts payable to OCD from IDEXX pursuant to this Agreement are overdue, other than amounts

23

 

												
	 	 	 	that are being disputed in good faith by IDEXX, then OCD shall be entitled to withhold such overdue amount (plus any accrued interest) from any rebate payments to which IDEXX may be entitled. Any overdue payments by OCD or IDEXX of any amounts owed to the other pursuant to this Section 7.03 shall bear interest at a rate per annum equal to the Prime Rate. Such interest shall be payable at the same time as the payment to which it relates and shall be calculated daily on the basis of a year of 365 days and the actual number of days elapsed.
	 			
	 	 	 	OCD shall prepare a remittance advice to accompany each rebate payment (or Reimbursement Notice), which shall set forth the reporting period for which the payment is made (or demanded) and a summary sheet which shall detail OCD’s calculation of the rebate (or reimbursement). If IDEXX disagrees with the rebate or reimbursement calculation, IDEXX shall promptly notify OCD, and the parties, together with IDEXX BV if appropriate, shall review the calculations together in good faith to agree on any appropriate corrections or adjustments.
	 			
	 	 	 	Any Special [**] Slides and any New Chemistry Slides shall be excluded from the determination of any rebate entitlement under Section 7.03 of this Agreement or the Europe Agreement, as the case may be, and the rebates described in Section 7.03 shall not apply to such slides.
	 			
	 	7.04	 	If IDEXX provides OCD with specific documentation regarding [**] that would require IDEXX and IDEXX BV, collectively, to purchase, in any calendar year, a number of slides over and above their most recent aggregate Annual Purchase Forecast for such year, [**] for slides, [**] for slides [**] by this Agreement, OCD agrees, within two weeks of its receipt of all additional information that OCD may reasonably request regarding such [**], to inform IDEXX as to whether or not OCD [**] in respect of [**], the number of slides [**] for such slides, and any other related terms and conditions that OCD deems applicable. OCD shall consider such requests in good faith. OCD agrees that [**] IDEXX or IDEXX BV pursuant to [**], remain in effect with respect to [**] until such time as [**], as the case may be.

									
	8.	 	INVOICES AND PAYMENT

												
	 	8.01	 	OCD shall invoice IDEXX in respect of each order for the VETTEST slides upon completion by OCD of the delivery of such order. Each order shall be billed by OCD under one invoice in US dollars and payment shall be made by IDEXX in US dollars not later than thirty (30) days following the date of invoice.

									
	9.	 	EXCLUSIVITY

												
	 	9.01	 	OCD undertakes not to sell or otherwise supply, and to cause its affiliates not to sell or otherwise supply, any Dry Slides (whether or not such slides are finished or complete) bar-coded for use in any Analyzers to any person, firm or company

24

 

												
	 	 	 	other than IDEXX or its affiliates. The provisions of this Section 9.01 shall survive the termination of this Agreement unless all of the following shall be true: (i) prior to such termination IDEXX (or its permitted assignees) and its affiliates shall have ceased to market the VETTEST slides, (ii) such cessation shall not have been a consequence of action by OCD, and (iii) OCD shall have complied with its obligations under this Agreement prior to such termination.

	 			
	 	9.02	 	IDEXX undertakes not to market, and to cause its affiliates not to market, any Dry Slide for any chemistry identified on Schedule 5, as amended from time to time, other than Dry Slides obtained by such person directly from OCD, to the extent that the desired chemistries are available from OCD; provided that, for purposes of adjusting inventory levels according to unanticipated changes in regional demand, IDEXX may purchase from IDEXX BV VETTEST slides that IDEXX BV obtained directly from OCD.

	 			
	 	9.03	 	(a) In consideration of the mutual obligations and commitments of the parties, IDEXX shall not actively promote, and shall cause IDEXX Parent and the other persons listed on Schedule 11 not to actively promote, the sale within the Exclusivity Territory of any Dry Slide for any chemistry identified on Schedule 5, as amended from time to time, or any instruments for use with any such Dry Slides, to any person (other than OCD and its affiliates) other than for use in the field of diagnostic testing of non-human animals. IDEXX may in its discretion terminate this provision at any time on [**] years’ prior written notice to OCD; provided that such notice may not be delivered until after June 30, [**].

												
	 	 	 	(b) Should OCD sell or cause to be sold for use in the field of diagnostic testing of non-human animals any product whose scope includes four or more of the chemistries identified on Schedule 5, then IDEXX may, in its sole discretion, terminate the provisions of Section 9.03(a) immediately upon written notice to OCD. If IDEXX delivers such notice of termination of Section 9.03(a) under this Section 9.03(b), then OCD may in its discretion terminate the provisions of Section 9.04(a) of this Agreement immediately upon written notice to IDEXX.

												
	 	9.04	 	(a) In consideration of the mutual obligations and commitments of the parties, OCD shall not actively promote, and shall cause the other persons (which for purposes of this clause may be divisions of OCD’s affiliates) listed on Schedule 12 not to actively promote, the sale within the Exclusivity Territory of any Dry Slide for any chemistry identified on Schedule 5, as amended from time to time, or any instruments for use with any such Dry Slides, to any person (other than IDEXX and its affiliates) for use in the field of diagnostic testing of non-human animals; provided that this provision shall not apply to (i) any instruments weighing more than 200 pounds, or to any slides sold for use on such instruments, unless and until the parties have executed the distribution agreement contemplated by Section 10.04 hereof and (ii) Ortho-Clinical Diagnostics K.K. until January 1, 2004. OCD may in its discretion terminate this provision at any time on [**]

25

 

												
	 	 	 	years’ prior written notice to IDEXX; provided that such notice may not be delivered until after June 30, [**]. The minimum purchase obligations of IDEXX shall terminate upon delivery of such a notice of termination.

												
	 	 	 	(b) Should IDEXX fail to sell at least [**] units of the New Analyzer before December 31, [**], then OCD may in its discretion terminate the provisions of Section 9.04(a) immediately upon written notice to IDEXX delivered after December 31, [**]; provided, that if OCD does not deliver such notice before IDEXX sells [**] units of the New Analyzer, then the provisions of this Section 9.04(b) shall be of no further effect. If IDEXX can demonstrate that it has expended in excess of $[**] on the development of the New Analyzer from the Effective Date through December 31, [**], then IDEXX shall be given an additional [**] to sell the requisite [**] units of the New Analyzer. If OCD delivers such notice of termination of Section 9.04(a) under this Section 9.04(b), then IDEXX may in its discretion terminate the provisions of Section 9.03 of this Agreement immediately upon written notice to OCD.
	 			
	 	 	 	(c) Should IDEXX sell or cause to be sold for use in the field of diagnostic testing of non-human animals any product, other than the New Analyzer, whose scope includes four or more of the chemistries identified on Schedule 5, then OCD may, in its sole discretion, terminate the provisions of Section 9.04(a) immediately upon written notice to IDEXX. If OCD delivers such notice of termination of Section 9.04(a) under this Section 9.04(c), then IDEXX may in its discretion terminate the provisions of Section 9.03(a) of this Agreement immediately upon written notice to OCD.

	 			
	 	 	 	(d) Notwithstanding any other provision of this Section 9.04, OCD and its affiliates shall continue to have the right to sell, directly or through distributors, VITROS analyzers and VITROS slides to all persons that are current VITROS end-user customers as of the Commencement Date, and to renew or extend the term of any contracts with such end-user customers or, solely for the purpose of sales to such end-user customers, with such distributors.

												
	 	9.05	 	OCD shall use commercially reasonable efforts to (i) ensure that no OCD Dry Slides (including without limitation VITROS slides to which bar coding for use in any Analyzer has been added) are supplied, marketed, distributed or sold, by anyone other than IDEXX or its affiliates and their respective authorized distributors, for use in the Analyzers and (ii) promptly enjoin or otherwise terminate any such supplying, marketing, distribution or sale. Notwithstanding the foregoing, OCD’s obligation to use commercially reasonable efforts for the purposes of this Section 9.05 shall not include any obligation to reduce non-VETTEST VITROS slide prices.
	 			
	 	 	 	OCD shall, where permitted by applicable law, use commercially reasonable efforts to include a provision in future supply and distributor contracts, that if a

26

 

												
	 	 	 	customer opens a mainframe slide cartridge and otherwise repackages or modifies OCD slides for a use other than for which the slides are sold by OCD, such activity, if not ceased upon notice, shall give OCD the right to terminate such contract. OCD will use commercially reasonable efforts to exercise such right where the customer does not cease such activity after due notice and a reasonable opportunity to cure. OCD and IDEXX shall also reasonably cooperate in efforts to stop any such unauthorized slide repackaging or modification, where the modified or repackaged slides are supplied, marketed or sold for use in Analyzers.
	 			
	 	 	 	In the event of a breach by OCD of this Section 9.05, OCD shall pay IDEXX, as IDEXX’s exclusive remedy for such breach, an amount equal to $[**] per slide sold for use in the Analyzers in breach of this Section 9.05.
	 			
	 	9.06	 	Within ninety (90) days of the date that either party (for purposes of this Section 9.06, the “Introducing Party”) (i) builds or acquires a prototype of any veterinary clinical chemistry diagnostic instrument that is designed to analyze [**] or more of the chemistries identified on Schedule 5 (a “Veterinary Diagnostic Product”) or (ii) has expended $[**] on a formal development project, or the acquisition of technology, for a Veterinary Diagnostic Product, such Introducing Party shall provide to the other party written notice of such decision. In addition, IDEXX agrees to provide such a notice if IDEXX Parent or IDEXX BV takes any of the actions described in clauses (i) or (ii) of this paragraph.

	 			
	 	9.07	 	During the Term of this Agreement, neither party shall directly recruit or otherwise directly solicit for employment (or instruct any third party so to do) any U.S. sales representative or first line sales manager of the other party ; provided that the foregoing shall not prohibit any advertisement or general solicitation or recruitment activity (or any hiring pursuant thereto) that is not specifically targeted at such persons.

									
	10.	 	MARKETING ARRANGEMENTS

												
	 	10.01	 	IDEXX will be responsible for all marketing arrangements for the Analyzers and the VETTEST slides. IDEXX may appoint any of OCD’s medical/surgical dealers as distributors of or agents for the Analyzers and the VETTEST slides but will not be obliged to do so.
	 			
	 	10.02	 	IDEXX will be responsible for the establishment of dealer performance criteria for all dealers including OCD’s medical/surgical dealers (if any are appointed by IDEXX as distributors of the Analyzers and the VETTEST slides).
	 			
	 	10.03	 	IDEXX will keep OCD informed of and consult with OCD as to marketing arrangements for the Analyzers and the VETTEST slides but will not be obligated to OCD beyond the terms of this Agreement in connection with such marketing arrangements.

27

 

												
	 	10.04	 	OCD hereby grants to IDEXX the exclusive right to distribute, solely in the veterinary market, under the terms set forth in this Section 10.4, VITROS slides and VITROS analyzers that run solely VITROS slides. The parties also agree to use good faith, commercially reasonable efforts to negotiate a definitive distribution agreement not later than December 31, 2003. OCD agrees to refer any inquiries for VITROS analyzers in the veterinary market to IDEXX, and shall not accept any orders for such analyzers in the veterinary market. IDEXX agrees to refer any inquiries for VITROS analyzers outside the veterinary market to OCD, and shall not accept any orders for such analyzers outside the veterinary market. Notwithstanding any other provision of this Section 10.04, OCD and its affiliates shall continue to have the right to sell, directly or through distributors, VITROS analyzers and VITROS slides to all persons that are current VITROS end-user customers as of the Commencement Date, and to renew or extend the term of any contracts with such customers or, solely for the purpose of sales to such customers, with such distributors.
	 			
	 	 	 	The parties shall discuss terms for any sales opportunity in the veterinary market in good faith, on a case-by-case basis. OCD shall be responsible, at its sole expense, for providing warranty and out-of-warranty service and support to any customers to whom IDEXX sells a VITROS analyzer; provided that such analyzer is then covered by a maintenance agreement between OCD and that customer. IDEXX shall not modify or customize any VITROS product supplied hereunder, or remove or alter any product labels or re-label any products, packaging or related materials for VITROS product supplied hereunder. OCD shall provide IDEXX, without charge, with such training in the marketing and sale of VITROS products and with such marketing and technical assistance and product information as OCD may, in its discretion, consider necessary to assist with the promotion and sale of the products; provided that OCD’s training obligation shall be limited to training employees of IDEXX to train other IDEXX employees and sales agents.
	 			
	 	 	 	IDEXX shall defend and indemnify OCD from and against all damages, liabilities, costs and expenses (including reasonable attorneys’ fees and costs) arising out of any claim resulting from (a) any negligent act or omission or any willful misconduct by IDEXX in connection with the VITROS products supplied by OCD under this Section 10.04 or (b) any statement, representation or warranty made by IDEXX or any of its agents with respect to a VITROS product that is not contained in the labeling or package insert and is not otherwise approved by OCD in writing or (c) any breach of IDEXX’s covenants in the preceding paragraph. OCD shall defend and indemnify IDEXX from and against all damages, liabilities, costs and expenses (including reasonable attorneys’ fees and costs) arising out of any claim (i) for injuries or death to persons or animals or damage to or destruction of tangible property arising out of the use of VITROS products sold under this Section 10.04 (whether claimed by reason of breach of warranty, negligence,

28

 

												
	 	 	 	product defect or other similar cause of action, regardless of the form in which any such claim is made) or (ii) that any VITROS product sold under this Section 10.04 infringes a patent, copyright, trademark or trade secret of a third party; provided that this clause (ii) shall not apply to any claim arising out of the use of any product in conjunction with products not supplied by OCD. The indemnity procedures set forth in Section 16.06 shall apply to this Section 10.04.
	 			
	 	 	 	The provisions of this Section 10.04 shall apply only within the Exclusivity Territory. Furthermore, the provisions of this Section 10.04 granting IDEXX exclusivity or restricting sales or marketing by or on behalf of OCD shall, (a) automatically terminate immediately upon the termination of Section 9.04(a) and (b) not apply to (i) any instruments weighing more than 200 pounds, or to any slides sold for use on such instruments, unless and until the parties have executed the distribution agreement contemplated by this Section 10.04 and (ii) Ortho-Clinical Diagnostics K.K. until January 1, 2004.

									
	11.	 	SALES SUPPORT

												
	 	11.01	 	IDEXX will be responsible for all necessary sales support for the Analyzers and the VETTEST slides.
	 			
	 	11.02	 	OCD’s sole obligation in respect of sale support shall be at its own expense to assist IDEXX in resolving specific problems resulting from the failure of VETTEST slides to conform to specifications.

									
	12.	 	TESTING

												
	 	12.01	 	01 OCD shall disclose to IDEXX its quality assurance procedures used in final evaluation of the VETTEST slides and full particulars thereof as set out in the VETTEST Slide Quality Assurance Procedures forming Schedule 1 to this Agreement. OCD shall operate such quality assurance procedures in accordance with Schedule 1.

	 			
	 	12.02	 	Upon prior written notice from IDEXX, OCD shall grant authorized representatives of IDEXX access to that part of OCD production facilities which conducts final evaluation of the VETTEST slides for the purpose of enabling such representatives to monitor the application by OCD of the VETTEST Slide Quality Assurance Procedures set out in Schedule 1. Such access shall be granted by OCD to IDEXX and IDEXX BV no more than twice in any twelve-month period. With respect to VETTEST slides for use in the New Analyzer, IDEXX shall be permitted to monitor those stages of the production process that are unique to VETTEST slides for the New Analyzer, but with respect to VETTEST slides for the VETTEST Analyzer, such access shall be limited to OCD’s final evaluation facilities. All information obtained as a result of the audits contemplated by this Section 12.02 shall be subject to the provisions of Schedule 2.

29

 

									
	13.	 	BAR CODING AND PACKAGING

												
	 	13.01	 	The VETTEST slides shall be printed by OCD with special bar coding for use in Analyzers.
	 			
	 	13.02	 	OCD shall package the VETTEST slides and tips for the VETTEST Analyzer in the physical manner as used for the VITROS slides and tips at the time of packaging of such VETTEST slides and tips. In the event of a change in VITROS slide or tip packaging which has an impact on such VETTEST slide or tip packaging, OCD shall notify IDEXX as early as practicable of the relevant particulars of such change.
	 			
	 	13.03	 	Except as authorized by Section 14.01 below, the label content and art work associated with VETTEST slides and package materials (including without limitation package materials for the New Slides) shall not include any trademarks, trade names, or trade dress of OCD. IDEXX shall furnish such label content and art work to OCD on a timely basis, and such label content and art work shall not be changed at any time during the Term without the prior agreement of the parties.

									
	14.	 	TRADE MARKS AND TRADE NAMES

												
	 	14.01	 	01 OCD expressly authorizes IDEXX to use the phrase “manufactured by Ortho-Clinical Diagnostics, Inc. for IDEXX (IDEXX ADDRESS)” on package materials for VETTEST slides (including without limitation package materials for the New Slides). No other uses of OCD’s trademarks, trade names or trade dress are authorized by this Agreement.
	 			
	 	14.02	 	IDEXX shall neither acquire, nor claim any right, title or interest in or to any of OCD’s trade marks or trade names by virtue of this Agreement or through advertising and sale of the Analyzers or the VETTEST slides or otherwise.

									
	15.	 	PATENT INDEMNITIES

												
	 	15.01	 	OCD shall indemnify and hold IDEXX harmless for all loss, damage, cost and expense whatsoever, including legal fees, patent attorney’s fees and court costs that IDEXX may incur or become liable for as a result of any action, suit or claim alleging infringement of any patent held by a third party arising from the use and/or sale of the VETTEST slides or tips to the extent that such action, suit, or claim relates in a material way to the specification for the VITROS slides or tips. If as a result of any judgment or settlement it is determined that a claim or claims of a third party patent is infringed by the use and/or sale of the VETTEST slides or tips as aforesaid and IDEXX is required to make any payments to any third party as a result thereof, IDEXX may off-set all such payments against any present and/or future payments to be made to OCD hereunder.

30

 

												
	 	15.02	 	IDEXX shall indemnify and hold OCD harmless for all loss, damage, cost and expense whatsoever, including legal fees, patent attorney’s fees and court costs that OCD may incur or become liable for as a result of any action, suit or claim alleging infringement of any patent held by a third party arising from (a) the manufacture, use or sale of the VETTEST slides or tips to the extent that the VETTEST slides or tips differ from the VITROS slides or tips, (b) the manufacture, use or sale of the New Slide/Panel Design, or (c) the manufacture, use or sale of any Analyzer.
	 			
	 	15.03	 	All claims for indemnity under this Article 15 shall be subject to the rights, obligations and procedures set forth in Section 16.06 below.

									
	16.	 	WARRANTY, LIABILITY AND INDEMNIFICATION

												
	 	16.01	 	OCD hereby warrants that:
	 			

												
	 	(a)	 	the VETTEST slides delivered to IDEXX shall be in compliance with Schedule 1, and

	 			
	 	(b)	 	OCD shall pack and ship products under this Agreement in a manner consistent with OCD’s usual practices, which shall be sufficient to protect the products from damage during normal shipping and handling.
	 			

												
	 	16.02	 	In the event of a breach on the part of OCD of Section 16.01 above, OCD’s liability shall be limited to the replacement of the VETTEST slides or tips found to be defective, including shipping costs for return of defective slides or tips and delivery of replacement slides or tips.
	 			
	 	16.03	 	OCD’s liability as stated in Section 16.02 shall be subject to the following conditions:
	 			

												
	 	(a)	 	IDEXX shall notify OCD promptly of any noncompliance contrary to Section 16.01(a) or damage contrary to Section 16.01(b).
	 			
	 	(b)	 	IDEXX and its transferees shall not alter or modify the VETTEST slides or packaging of the VETTEST slides or tips without prior approval of OCD.
	 			

												
	 	16.04	 	Except as provided in this Section 16 there are no other warranties, express or implied, including warranties for fitness for any particular use or of merchantability.
	 			
	 	16.05	 	Subject to Section 15, IDEXX shall indemnify and hold harmless OCD from and against any claim, loss, damage, or expense (including attorney’s fees) with

31

 

												
	 	 	 	respect to any physical injury to persons, animals or property arising out of or in connection with IDEXX’s use or sale of any Analyzer or the VETTEST slides, and any claim of infringement of any trademark (except OCD’s own trademark), trade dress, trade secret, or copyright. IDEXX shall notify OCD (a) at the commencement of any action or suit based on any such claim and (b) in the event of any injunction or other order prohibiting the sale or use of any Analyzer or VETTEST slide.
	 			
	 	16.06	 	Any party claiming indemnification under this Agreement (the “Indemnitee”) shall notify the party from which indemnification is claimed (the “Indemnifying Party”) in writing promptly upon becoming aware of any claim to which such indemnification may apply. Failure to provide such notice shall constitute a waiver of the Indemnifying Party’s indemnity obligations hereunder if, and only to the extent that, the Indemnifying Party is materially damaged thereby. The Indemnifying Party shall have the right to assume and control the defense of the claim at its own expense. If the right to assume and have sole control of the defense is exercised, the Indemnitee shall have the right to participate in, but not to control, such defense at its own expense. If the Indemnifying Party does not assume the defense of the claim, the Indemnitee may defend the claim at the Indemnifying Party’s expense. The Indemnitee will not settle or compromise the claim without the prior written consent of the Indemnifying Party. The Indemnifying Party will not, without the consent of the Indemnitee (which consent will not be unreasonably withheld), settle or compromise the claim in any manner which would have an adverse effect on the Indemnitee, unless (x) prior to such settlement or compromise the Indemnifying Party acknowledges in writing its obligation to pay in full the amount of the settlement or compromise and the Indemnitee is furnished with security reasonably satisfactory to it that the Indemnifying Party can in fact pay such amount, (y) such settlement or compromise includes a full release of such claim against the Indemnitee and (z) such settlement or compromise provides for no relief or remedy other than money damages. The Indemnitee shall reasonably cooperate with the Indemnifying Party and will make available to the Indemnifying Party all pertinent information under the control of the Indemnitee.

17.     SECRECY
												
	 	17.01	 	Each of IDEXX, IDEXX Parent and OCD agrees to protect confidential information disclosed to it upon terms set out in Schedule 2 attached hereto.

									
	18.	 	PERIOD OF AGREEMENT

												
	 	18.01	 	Subject to the terms and conditions set forth herein, the term (the “Term”) of the Agreement shall be the period from the Commencement Date until December 31, 2018.

32

 

									
	19.	 	TERMINATION

												
	 	19.01	 	This Agreement may be terminated by either party in any of the following events:
	 			

												
	 	(a)	 	If the other party is guilty of gross or persistent breaches of the terms of this Agreement, which breaches are not remedied to the satisfaction of the other party after ninety (90) days notice in writing to do so. Any such breach shall entitle the innocent party to terminate this Agreement by notice in writing which notice shall be effective at the end of ninety (90) days following the date of such notice.
	 			
	 	(b)	 	If the other party becomes insolvent or compounds with its creditors or goes into liquidation (other than for the purposes of corporate reorganization) then the innocent party may terminate this Agreement by notice in writing which shall have immediate effect.
	 			
	 	(c)	 	If such party elects to cease marketing Dry Slide diagnostic products, then it shall have the right, by notice given at any time after January 1, [**], to terminate this Agreement upon[**] years’ prior written notice.
	 			

												
	 	19.02	 	Changes in the equity ownership or corporate reorganizations of either party shall not be grounds for termination of this Agreement, except that if more than [**]% of the outstanding capital stock of IDEXX or IDEXX Parent is owned or controlled by a competitor of OCD, OCD may in its discretion terminate the provisions of Sections 9.04 and 10.04 of this Agreement immediately upon written notice to IDEXX. If OCD delivers such notice of termination under this Section 19.02, then IDEXX may in its discretion terminate the provisions of Section 9.03 of this Agreement immediately upon written notice to OCD.
	 			
	 	19.03	 	This Agreement shall terminate automatically upon any termination of the Europe Agreement.
	 			
	 	19.04	 	The provisions of this Agreement dealing with rights and obligations after termination of this Agreement, including without limitation Sections 3.04, 3.05, 3.06, 3.07, 15, 16, 17, 21, 22, 23, 24, 25, 26, 29 and 30, shall survive the expiration or termination of this Agreement and continue to be enforceable to the extent necessary to achieve the logical and intended purposes of such provisions.

									
	20.	 	FORCE MAJEURE

												
	 	20.01	 	Neither party shall be liable for any failure or delay in performing any of its respective obligations under this Agreement to the extent that such failure or delay is due to any cause beyond its reasonable control (a “Force Majeure Event”). The non-performing party shall give the other party prompt written notice of such inability to perform and shall use commercially reasonable efforts to resume

33

 

												
	 	 	 	performance as soon as reasonably practicable. If as a result of a Force Majeure Event OCD is unable, using commercially reasonable efforts, to meet its supply obligations to IDEXX hereunder for a period exceeding twenty-four months, or if IDEXX reasonably determines that it will not be feasible for OCD through the use of commercially reasonable efforts to resume the supply of VETTEST slides within twenty-four months, then either party may terminate this Agreement immediately upon written notice to the other party.

									
	21.	 	GOVERNING LAW; JURISDICTION

												
	 	21.01	 	The construction, validity and performance of this Agreement shall be governed in all respects by the laws of the State of New York, USA. Any legal actions relating to this Agreement must be brought in the court of appropriate jurisdiction in the State of New York, which shall have exclusive jurisdiction, and the parties hereby waive any claim of lack of jurisdiction or inconvenient forum. The prevailing party in any litigation under this Agreement shall be entitled to an award of its costs, including reasonable attorneys’ fees and expenses. Each party hereto waives its right to trial of any issue by jury. Each party hereto waives any claim to punitive, exemplary or multiplied damages from the other. Each party hereto waives any claim of consequential damages from the other.

									
	22.	 	SEVERABILITY

												
	 	22.01	 	Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, then the parties agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration, or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified after the expiration of the time within which the judgment may be appealed.

									
	23.	 	WAIVERS

												
	 	23.01	 	Failure of either party to this Agreement to insist upon strict observance or compliance with all its terms and conditions in one or more instances shall not be deemed to be a waiver of its right to insist upon such observance or compliance with such term or condition or with any other terms or conditions hereof in the future.

34

 

									
	24.	 	PRIOR AGREEMENTS; INTERPRETATION

												
	 	24.01	 	As of the Commencement Date, this Agreement shall take effect in substitution for the Prior US Agreement, the Operations Agreement (except as otherwise provided in Section 7.04 of this Agreement), Section B (Amendments) of the Settlement Agreement, and all or any other previous agreements relating to the subject matter hereof whether the same are formal agreements or agreements that would be inferred from the parties’ correspondence or conduct, and all such substituted agreements shall be deemed to have been terminated by mutual consent on the Commencement Date; provided, however, that nothing contained herein shall be deemed to modify or terminate the Europe Agreement, except that the Purchase Commitments and Annual Purchase Forecasts referred to in Section 5 and in Schedule 4 of this Agreement and the Europe Agreement represent the aggregate commitments and forecasts of IDEXX and IDEXX BV and not the individual commitments and forecasts of IDEXX BV under the Europe Agreement or IDEXX under this Agreement.

									
	25.	 	ENTIRE AGREEMENT

												
	 	25.01	 	This Agreement, together with the Europe Agreement, the Settlement Agreement (other than Section B thereof), and that certain memorandum agreement dated September 12, 2003 regarding slide packaging (as amended to date), constitutes the complete agreement of the parties concerning the subject matter hereof and thereof during the Term, and, with respect to all periods from and after the Commencement Date, supersedes all prior agreements between the parties regarding its subject matter.

									
	26.	 	ALTERATION OR MODIFICATION

												
	 	26.01	 	No alteration, amendment or modification to this Agreement or the attached Schedules shall be of any force or effect unless in writing and signed by both parties. No modification shall be effected by the acknowledgement or acceptance of purchase order forms or order confirmations or invoices or other documents containing different conditions.

									
	27.	 	ASSIGNMENT

												
	 	27.01	 	This Agreement shall not be capable of assignment by either party to a company of which it owns less than a majority or which owns less than a majority of the party save in the case of (i) an assignment at OCD’s sole discretion to an acquiror of OCD’s dry slide business or (ii) an assignment at IDEXX’s sole discretion to an acquiror of IDEXX’s VETTEST and New Analyzer business; provided that no assignment shall release the assigning party from any obligations hereunder. In the case of an assignment under the preceding clause (ii) to an entity which is a competitor of OCD’s diagnostics business, OCD may in its discretion terminate

35

 

												
	 	 	 	the provisions of Section 9.04 of this Agreement immediately upon written notice to IDEXX. If OCD delivers such notice of termination of Section 9.04 under this Section 27.01, then IDEXX’s assignee may in its discretion terminate the provisions of Section 9.03 of this Agreement immediately upon written notice to OCD.
	 			
	 	 	 	This Agreement shall be binding on and inure to the benefit of the parties hereto and their permitted successors and assigns.

									
	28.	 	GOVERNING LANGUAGE

												
	 	28.01	 	[Reserved]

									
	29.	 	NOTICES

												
	 	29.01	 	Any notice, statement or other communication to be given by one party to the other hereunder may be given by registered mail, airmail, nationally recognized courier, facsimile or telex to the party concerned at the addresses set out below:
	 			
	 	 	 	Ortho-Clinical Diagnostics, Inc.
1001 US Highway 202
Raritan, New Jersey 08869, USA
For the attention of: Vice President and General Manager, Americas
	 			
	 	 	 	With a copy to:
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933, USA
For the attention of: Office of General Counsel
	 			
	 	 	 	IDEXX Operations, Inc.
6100 East Shelby Drive
Memphis, Tennessee 38141, USA
For the attention of: President
	 			
	 	 	 	With a copy to:
IDEXX Laboratories, Inc.
One IDEXX Drive
Westbrook, Maine 04092, USA
For the attention of: Office of General Counsel
	 			
	 	29.02	 	Any notice, payment or communication so given or made shall be deemed to have been received at the time when in the ordinary course of transmission the same should have reached its destination. Either party may change its address for the

36

 

												
	 	 	 	purpose of this Agreement by giving notice of such change to the other party pursuant to the provisions of this Section. For purposes of this Section 29, notice given by OCD to IDEXX BV under the Europe Agreement shall be deemed given to IDEXX.

									
	30.	 	GUARANTY

												
	 	30.01	 	IDEXX Parent hereby guarantees to OCD the due performance and observance by IDEXX of all of the provisions of the Agreement to be performed and observed by it under this Agreement, for which IDEXX Parent shall be jointly and severally liable, without requiring any notice of non-payment, non-performance or non-observance, or proof of notice or demand, all of which IDEXX Parent hereby waives. OCD may proceed against IDEXX Parent separately or jointly, before, after or simultaneously with proceeding against IDEXX for default. This guaranty shall not be terminated, affected or impaired in any way by reason of (i) the assertion by OCD against IDEXX of any of the rights or remedies reserved to OCD under this Agreement, (ii) the commencement by OCD of any proceedings against IDEXX, (iii) the granting by OCD of any extensions of time or indulgence to IDEXX, (iv) any change in or amendment to this Agreement, or (v) any payment or performance being invalid in connection with any bankruptcy, insolvency, reorganization or similar proceedings in respect to IDEXX. This guaranty is absolute and unconditional and shall continue in full force and effect as to any renewal, extension, amendment, addition, assignment or transfer or other modification of this Agreement, whether or not IDEXX Parent shall have been notified of or consented to any such action, and regardless of bankruptcy or insolvency of IDEXX or the actual or purported rejection by a trustee in such bankruptcy of this Agreement or any limitation on any claim in such bankruptcy for damages resulting from the actual or purported termination of this Agreement or the enforceability in such bankruptcy of this Agreement. IDEXX Parent hereby agrees that this guaranty shall continue to be effective or shall be reinstated, as the case may be, if at any time payment of any sum hereby guaranteed is rescinded or must be otherwise restored or returned by OCD upon the insolvency, bankruptcy or reorganization of IDEXX, or otherwise, all as though such payment had not been made.

37

 

     IN WITNESS WHEREOF and intending to be legally bound, the parties hereto have caused this Agreement to be duly executed in duplicate by their respective authorized representatives the day and year first written above.
												
	 	 	 	 
	ORTHO-CLINICAL	IDEXX OPERATIONS, INC.
	DIAGNOSTICS, INC.	 	 
	 	 	 	 
	By:	 /s/ Tony Zezzo
	By:	 /s/ Conan R. Deady

	 		 	
	 	Tony Zezzo,	 	Conan R. Deady,
	 	Vice President and General Manager,	 	Vice President
	 	Americas	 	 
	 	 	 	
	 	 	 	Solely as to Sections 17 and 30
	 	 	 	IDEXX LABORATORIES, INC.
	 	 	 	 
	 	 	By:	 /s/ Jonathan W. Ayers

	 	 	 	
	 	 	 	Jonathan W. Ayers,
	 	 	 	President and Chief Executive Officer

38

 

Schedule 1 – VetTest® Slide Quality Assurance Procedures
VETTEST Slides for the VETTEST Analyzer:
Introduction
The following procedure constitutes a generic overview of the quality assurance provisions for finishing of VITROS slides and applies in like manner to product release for the VETTEST slides.
VETTEST Slide Quality Assurance
VETTEST slides will be produced to the same quality standards as VITROS and DT 60 slides for OCD’s human market unless otherwise agreed to by IDEXX.
Bar Coding
Bar code printing on the VETTEST slides will render the VETTEST slides incompatible with use in VITROS analyzers. OCD will reserve certain number sequences for generation of the bar code patterns on the VETTEST slides.
New Slides:
Specifications to be determined by IDEXX as part of the Development Program and, together with quality assurance procedures, reasonably agreed in writing by the parties for purposes of this Schedule 1.
39

 

Schedule 2
     Section 1. Obligation to Keep Information Confidential. Each party agrees to hold, and to cause its respective officers, directors, employees, accountants, counsel, consultants, advisors and agents to hold, in confidence the terms of the Agreements, and all documents and information concerning the other party, whether oral or written, furnished or made known to such party in connection with either of the Agreements or any project or discussion under, or related to, either of the Agreements; provided that no party shall be required to keep any information confidential (i) if such party is compelled to disclose such information by judicial or administrative process or by other requirements of law (including without limitation the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) and such party has provided prior written notice to the other party and given such other party reasonable opportunity to contest disclosure or (ii) to the extent such information can be shown to have been (A) previously known to such party on a nonconfidential basis, (B) in the public domain through no fault of such party, (C) later lawfully acquired from a third party source or (D) independently developed by such party without reference to confidential information. The foregoing notwithstanding, any party may disclose information concerning the other party or the Agreements to its and its affiliates’ officers, directors, employees, accountants, counsel, consultants, advisors and agents in connection with its performance of this Agreement so long as such persons are informed by such party of the confidential nature of such information and are directed by such party to treat such information confidentially, it being understood and agreed that such party shall be responsible for any failure to treat such information confidentially by such persons. The obligation of each party to hold any information in confidence shall be satisfied if it exercises the same care with respect to such information as it would to preserve the confidentiality of its own similar information. The confidentiality provisions of this Schedule 2 shall remain in effect for so long as this Agreement is in effect and for a period of three (3) years thereafter.
     Section 2. Public Announcements. No party to this Agreement shall originate any news release or other public announcement, written or oral, relating to this Agreement or the Europe Agreement, without the prior written consent of the other party, except to the extent such news release or other public announcement is required by law; provided that in the event an announcement is required by law, the party issuing same shall still be required to use its commercially reasonable efforts to consult with the other party or parties named or referred to in such announcement prior to its release as the circumstances reasonably permit, in order to allow such other party or parties to comment on the use of their names or the references to them and, after its release, shall provide such other party or parties with a copy thereof. If a party has previously reviewed and approved a public announcement, its further approval shall not be required with respect to those provisions of subsequent announcements that are substantially similar in scope and substance to provisions that have been previously approved. In no event shall IDEXX or IDEXX Parent use the name “Johnson & Johnson” or “J&J” in any publicity relating to this Agreement or the Europe Agreement, whether written or oral, other than to state that OCD is “a Johnson & Johnson company” or a (wholly-owned) subsidiary of Johnson & Johnson.
40

 

     Section 3. Governing Law. The construction, validity and performance of this Schedule 2 shall be governed in all respects by the laws of the State of New York, USA.
     Section 4. Notices. Any notices required to be given under this Schedule 2 shall be given in the manner specified by Section 29 of the Agreement.
41

 

Schedule 3 - Panels/Profiles
(Applicable only to VETTEST Analyzer)
The initial PANEL shall be the “Pre-Anesthetic Panel” consisting of four sets of the following six VETTEST slides:
									
	 	 	 
	BUN	 	Urea Nitrogen
	ALT	 	Alanine aminotransferase
	GLU	 	Glucose
	TP	 	Total protein
	CREA	 	Creatinine
	ALKP	 	Alkaline phosphatase

The initial PROFILES shall be the “General Health Profile” and the “Large Animal Profile”, each consisting of two sets of 12 VETTEST slides as follows:
																					
	 	 	 	 	 	 	 
	General Health Profile	 	Large Animal Profile
	 						
	ALB	 	Albumin	 	ALB	 	Albumin
	ALKP	 	Alkaline phosphatase	 	ALKP	 	Alkaline phosphatase
	ALT(SGPT)	 	Alanine aminotransferase	 	AST	 	AST
	AMYL	 	Amylase	 	Ca2+
	 	Calcium
	Ca2+
	 	Calcium	 	CK	 	CK
	CHOL	 	Cholesterol	 	GGT	 	Gamma GT
	CREA	 	Creatinine	 	GLU	 	Glucose
	GLU	 	Glucose	 	PHOS	 	Inorganic phosphate
	PHOS	 	Inorganic phosphate	 	LDH	 	LDH
	TBIL	 	Total bilirubin	 	MG	 	Magnesium
	TP	 	Total protein	 	TP	 	Total Protein
	BUN	 	Urea Nitrogen	 	BUN	 	Urea Nitrogen

Packaging for the Pre-Anesthetic Panels, the General Health Profiles and the Large Animal Profiles for the VETTEST Analyzer has been previously agreed upon by the parties, and any changes to the slide composition or packaging of the initial PANEL or the initial PROFILES shall be negotiated in good faith and mutually agreed upon by OCD and IDEXX. The slide composition, packaging and initial pricing of any additional PANELS/PROFILES shall be mutually agreed upon by OCD and IDEXX. Unless otherwise agreed by the parties in writing with respect to one or more specific PANELS or PROFILES, all purchases by IDEXX or IDEXX BV of VETTEST slides packaged as PANELS/PROFILES shall be credited against the Annual Purchase Forecasts and Purchase Commitments for such slides under this Agreement and the Europe Agreement.
New Slide/Panel Design for the New Analyzer shall be as developed by IDEXX under Article 3.
42

 

Schedule 4 - Purchase Commitments
															
	 	 	 	 	 
	 	 	Minimum Slide Purchase
	Year	 	Commitment ([**])
	
	 	

	2003
	 	 	[**]	 
	2004
	 	 	[**]	 
	2005
	 	 	[**]	 
	2006
	 	 	[**]	 
	2007
	 	 	[**]	 
	2008
	 	 	[**]	 
	2009
	 	 	[**]	 
	2010
	 	 	[**]	 

43

 

Schedule 5 - Products and Prices
(as of the Commencement Date)
																														
	 	 	 	 	 	 	 	 	 	 
	Sales Region	 	US Sales	 	Asian Sales	
	
	 	
	 	
	
	Customer Number
	 	 	164 9706	 	 	 	318 3258	 	

																																																			
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	US Pricing	 	 	 	 
	 	 	 	 	 	 	
	 	 	 	 
	 	 	 	 	 	 	>1500	 	 	 	 	 	 	 	 
	Single Slides (Bx 25)	 	Catalog Number	 	bxs*	 	<1500 bxs*	 	Asian Pricing
	
	 	
	 	
	 	
	 	

	Albumin
	 	 	822 7134	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Alk Phos
	 	 	831 5459	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	ALT
	 	 	808 3750	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Ammonia
	 	 	181 6842	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Amylase
	 	 	820 8191	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	AST
	 	 	811 3979	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Calcium
	 	 	804 8191	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Cholesterol
	 	 	835 4888	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	CK
	 	 	835 8582	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Creatinine
	 	 	818 3477	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	ECO2
	 	 	853 8670	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Gamma GT
	 	 	826 1315	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Glucose
	 	 	813 0536	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	LDH
	 	 	835 1082	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Lipase
	 	 	196 6191	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Magnesium
	 	 	108 0266	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Phosphorus
	 	 	807 0856	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Total Bilirubin
	 	 	838 0396	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Total Protein
	 	 	193 7093	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Triglycerides
	 	 	192 2285	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Urea Nitrogen
	 	 	150 7326	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	Uric Acid
	 	 	100 0793	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 

																																							
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Profile Slides (Bx 24)	 	Catalog Number	 	US Pricing	 	Asian Pricing
	
	 	
	 	
	 	

	General Health Profile
	 	 	160 7175	 	 	$	[**]	 	 	$	[**]	 
	Pre-Anesthetic Panel
	 	 	801 5109	 	 	$	[**]	 	 	$	[**]	 
	Large Animal Profile
	 	 	680 0071	 	 	$	[**]	 	 	$	[**]	 

																											
	 	 	 	 	 	 	 	 	 
	Other	 	Catalog Number	 	WW Pricing
	
	 	
	 	

	Vetrols
	 	 	869 9852	 	 	$	[**]	 
	Tips
	 	 	175 7384	 	 	$	[**]	 

									
	*	 	per chemistry per order

44
 
Schedule 5 - Products and Prices (continued)
Sales Region: Australia/New Zealand
Customer No.: 314 8251

																											
	 	 	 	 	 	 	 	 	 
	Single Slides (Box of 25)	 	Catalog Number	 	Australia/NZ Pricing
	
	 	
	 	

	Albumin
	 	 	822 7134	 	 	$	[**]	 
	Alk Phos
	 	 	831 5459	 	 	$	[**]	 
	ALT
	 	 	808 3750	 	 	$	[**]	 
	Ammonia
	 	 	181 6842	 	 	$	[**]	 
	Amylase
	 	 	820 8191	 	 	$	[**]	 
	AST
	 	 	811 3979	 	 	$	[**]	 
	Calcium
	 	 	804 8191	 	 	$	[**]	 
	Cholesterol
	 	 	835 4888	 	 	$	[**]	 
	CK
	 	 	835 8582	 	 	$	[**]	 
	Creatinine
	 	 	818 3477	 	 	$	[**]	 
	ECO2
	 	 	853 8670	 	 	$	[**]	 
	Gamma GT
	 	 	826 1315	 	 	$	[**]	 
	Glucose
	 	 	813 0536	 	 	$	[**]	 
	LDH
	 	 	835 1082	 	 	$	[**]	 
	Lipase
	 	 	196 6191	 	 	$	[**]	 
	Magnesium
	 	 	108 0266	 	 	$	[**]	 
	Phosphorus
	 	 	807 0856	 	 	$	[**]	 
	Total Bilirubin
	 	 	838 0396	 	 	$	[**]	 
	Total Protein
	 	 	193 7093	 	 	$	[**]	 
	Triglycerides
	 	 	192 2285	 	 	$	[**]	 
	Urea Nitrogen
	 	 	150 7326	 	 	$	[**]	 
	Uric Acid
	 	 	100 0793	 	 	$	[**]	 

																											
	 	 	 	 	 	 	 	 	 
	Profile Slides (Box of 24)	 	Catalog Number	 	Australia/NZ Pricing
	
	 	
	 	

	General Health Profile
	 	 	160 7175	 	 	$	[**]	 
	Pre-Anesthetic Panel
	 	 	801 5109	 	 	$	[**]	 
	Large Animal Profile
	 	 	680 0071	 	 	$	[**]	 

																											
	 	 	 	 	 	 	 	 	 
	Other	 	Catalog Number	 	WW Pricing
	
	 	
	 	

	Vetrols
	 	 	869 9852	 	 	$	[**]	 
	Tips
	 	 	175 7384	 	 	$	[**]	 

45

 

Schedule 6 – Minimum Prices for New Chemistries
46

 
Schedule 7 - Illustrative Rebate Calculations
The Estimated Rebate Payments will be calculated for each of the first three calendar quarters using the Effective Rebate Rate, as described more fully in sub-clause 7.03 of the Agreement. Any required adjustments will be made at the end of the fourth calendar quarter, in accordance with sub-clause 7.03 of the Agreement.
Example: The aggregate Annual Purchase Forecast for IDEXX and IDEXX BV in a given year is [**] slides; pricing is $[**]/slide; blended rebate percentage rate is [**]%, as follows:
									
	 	 	[**] slides * [**]% = [**] slides
	 		
	 	 	[**] slides * [**]% = [**] slides
	 		
	 	 	[**] slides * [**]% = [**] slides
	 		
	 	 	[**] slides * [**]% = [**] slides
	 		
	 	 	[**] slides * [**]% = [**] slides

	 		
	 	 	Total Slides Eligible for Rebate = [**] slides
	 		
	 	 	Effective Rebate = Total slides eligible for rebate / total purchases = [**] = [**]%

Actual aggregate volume purchased by IDEXX and IDEXX BV equals volume projected at the beginning of the year.
																																																																											
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Actual Qtrly.	 	 	 	 	 	 	 	 	 	Calculated	 	[**]%	 	
	 	 	Vol.	 	Purchases	 	Effective Rebate	 	Rebate Each	 	Holdback	 	Rebate Paid
	 	 	([**])	 	($[**])	 	% ([**] Vol.)	 	Qtr. ([**])	 	([**])	 	([**])
	 	 	
	 	
	 	
	 	
	 	
	 	

	1st Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	2nd Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	3rd Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	4th Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	 
	 	 	[**]	 	 	$	[**]	 	 	 	 	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	True-up:	 	$	[**]	 	 	 	 	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	Total:	 	$	[**]	 	 	 	 	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	
	 

Actual aggregate volume purchased by IDEXX and IDEXX BV is greater than volume projected at the beginning of the year.
																																																																											
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Actual Qtrly.	 	 	 	 	 	 	 	 	 	Calculated	 	[**]%		 
	 	 	Vol.	 	Purchases	 	Effective Rebate	 	Rebate Each	 	Holdback	 	Rebate Paid
	 	 	([**])	 	($[**])	 	% ([**] Vol.)	 	Qtr.([**])	 	([**])	 	([**])
	 	 	
	 	
	 	
	 	
	 	
	 	

	1st Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	2nd Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	3rd Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	4th Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	 
	 	 	[**]	 	 	$	[**]	 	 	 	 	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	True-up:	 	$	[**]	 	 	 	 	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	Total:	 	$	[**]	 	 	 	 	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	
	 

47

 

Actual aggregate volume purchased by IDEXX and IDEXX BV is lower than volume projected at the beginning of the year.
																																																																											
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Actual Qtrly.	 	 	 	 	 	 	 	 	 	Calculated	 	[**]%		 
	 	 	Vol.	 	Purchases	 	Effective Rebate	 	Rebate Each	 	Holdback	 	Rebate Paid
	 	 	([**])	 	($[**])	 	% ([**] Vol.)	 	Qtr. ([**])	 	([**])	 	([**])
	 	 	
	 	
	 	
	 	
	 	
	 	

	1st Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	2nd Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	3rd Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	4th Qtr
	 	 	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	 
	 	 	[**]	 	 	$	[**]	 	 	 	 	 	 	$	[**]	 	 	$	[**]	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	True-up:	 	$	[**]	 	 	 	 	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	Total:	 	$	[**]	 	 	 	 	 	 	$	[**]	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	
	 

Calculation of IDEXX’s Proportionate Share of rebate (assuming Actual aggregate volume purchased by IDEXX and IDEXX BV equals volume projected at the beginning of the year):
Assumptions:
									
	•	 	Number of slides purchased by IDEXX and its wholly-owned subsidiaries other than IDEXX BV: [**] slides
	 		
	•	 	Total number of slides purchase by IDEXX and its wholly-owned subsidiaries: [**] slides
	 		
	•	 	Total rebate earned: $[**]

Calculation:
IDEXX’s rebate equals: [**] slides / [**] slides * $[**], or $[**].
48

 

Schedule 8 – Eligible New Chemistry Slides
[**]
49

 

Schedule 9 - Example of Cost Adjustment Calculations
(Assumes PPI = [**]%)
																																																																																																			
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Scenario 1	 	Scenario 2
	 	 	 	 	 	 	 	 	 	 	
	 	

	 	 	% of OCD ’s	 	Year 1	 	% Change	 	Year 2	 	$ Change	 	% Change	 	Year 2	 	$ Change
	Costs	 	Usage	 	Cost	 	In Cost	 	Cost	 	in Cost	 	in Cost	 	Cost	 	in Cost
	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	

	[**]
	 	 	[**]	%	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 
	[**]
	 	 	[**]	%	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	-$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 
	[**]
	 	 	[**]	%	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 
	[**]
	 	 	[**]	%	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 
	[**]
	 	 	 	 	 	$	[**]	 	 	 	[**]	 	 	$	[**]	 	 	$	[**]	 	 	 	[**]	 	 	$	[**]	 	 	$	[**]	 
	 
	 	Total	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 
	 
	 	Total (x[**])	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 	 	 	[**]	%	 	$	[**]	 	 	$	[**]	 

Scenario 1 Conclusion: [**]Cost Adjustment Required (Other Costs Increased by < [**]% over PPI)
																		
	 	 	 	 	 	 
	Adjustment Calculation [**]:
	 	 	 	 
	Actual [**]
	 	$	[**]	 
	Less: PPI Change ([**]% of $[**])
	 	$	[**]	 
	 	Total Adjustment
	 	$	[**]	 

Scenario 2 Conclusion: [**] Costs Adjustments Required
																		
	 	 	 	 	 	 
	Adjustment Calculation [**]:
	 	 	 	 
	Same as above
	 	$	[**]	 
	Adjustment for [**] Costs:
	 	 	 	 
	Actual Cost Change
	 	$	[**]	 
	Less: “PPI Plus [**]%” Change ([**]% *$[**])
	 	$	[**]	 
	 	Adjustment
	 	$	[**]	 
	 	Total Adjustment
	 	$	[**]	 
	 
	 	 	
	 

* - [**] Costs - [**] $[**], or $[**]/slide @ [**] slides
50

 
Schedule 10 – Excluded Countries

									
	 	 	 
	Albania	 	Liechtenstein
	Andorra	 	Lithuania
	Armenia	 	Macedonia
	Azerbaijan	 	Malta
	Bahrain	 	Monaco
	Belarus	 	Norway
	Bosnia and Herzegovina	 	Oman
	Bulgaria	 	Pakistan
	Croatia	 	Poland
	Cyprus	 	Qatar
	Czech Republic	 	Romania
	Estonia	 	Russia
	Faroes Islands	 	San Marino
	Georgia	 	Saudi Arabia
	Hungary	 	Slovakia
	Iceland	 	Slovenia
	Iran	 	Switzerland
	Iraq	 	Syria
	Israel	 	Tajikistan
	Jordan	 	Turkey
	Kazakhstan	 	Turkmenistan
	Kuwait	 	Ukraine
	Kyrgyzstan	 	United Arab Emirates
	Latvia	 	Uzbekestan
	Lebanon	 	Yemen

51

 

Schedule 11 – IDEXX Entities
IDEXX Laboratories Canada Corporation (Canada)
IDEXX Laboratories Pty. Ltd. (Australia)
IDEXX Laboratories (NZ) Ltd. (New Zealand)
IDEXX Laboratories, KK (Japan)
IDEXX Laboratories (Taiwan) Inc. (Taiwan)
52

 

Schedule 12 – OCD Entities
Ortho-Clinical Diagnostics, a division of Janssen-Ortho Inc. (Canada)
Ortho-Clinical Diagnostics, a division of Johnson & Johnson Medical Pty. Limited (Australia)
Ortho-Clinical Diagnostics K.K. (Japan)
Ortho-Clinical Diagnostics, a division of Johnson & Johnson Limited (India)
Ortho-Clinical Diagnostics, a division of Johnson & Johnson Pte. Ltd. (Singapore)

[*] and [**] text omitted throughout this exhibit for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

53

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]